{
  "id": "903b29fc-0162-4283-843b-66877725e65d",
  "source": "claude",
  "title": "Amphetamine-based ADHD Medications in Belgium",
  "created_at": "2025-05-28T11:04:59.876555Z",
  "updated_at": "2025-05-28T11:18:30.093802Z",
  "summary": "",
  "message_count": 6,
  "messages": [
    {
      "id": "cdad6511-a58c-4707-a829-a45e83944092",
      "role": "human",
      "content": "What amphetamine based add medications are in Belgium?",
      "created_at": "2025-05-28T11:05:00.517897Z",
      "sequence_order": 0,
      "metadata": {
        "content": [
          {
            "start_timestamp": "2025-05-28T11:05:00.515026Z",
            "stop_timestamp": "2025-05-28T11:05:00.515026Z",
            "flags": null,
            "type": "text",
            "text": "What amphetamine based add medications are in Belgium?",
            "citations": []
          }
        ],
        "updated_at": "2025-05-28T11:05:00.517897Z",
        "attachments": [],
        "files": []
      }
    },
    {
      "id": "01a874b8-514b-4bc0-807b-2a75ae0878bd",
      "role": "assistant",
      "content": " I'll search for current information about amphetamine-based ADHD medications available in Belgium.\n```\nThis block is not supported on your current device yet.\n```\n\n\n\nLet me search more specifically for amphetamine-based medications available in Belgium.\n```\nThis block is not supported on your current device yet.\n```\n\n\n\nLet me search for more specific information about Belgium's available ADHD medications and their regulatory status.\n```\nThis block is not supported on your current device yet.\n```\n\n\n\nBased on my research, I can provide you with a clear picture of amphetamine-based ADHD medications in Belgium, though I should note that the availability appears to be quite limited compared to other countries.\n\n**Current Status of Amphetamine-Based ADHD Medications in Belgium:**\n\nThe evidence suggests that amphetamine-based medications have very limited availability in Belgium. Here's what I found:\n\n**Limited Availability:**\nMethylphenidate, better known by its brand name Ritalin, is currently the only ADHD drug that is reimbursed in Belgium for patients under the age of 18. The official FAMHP (Belgian health agency) list of commercialised stimulant medicines in Belgium includes: Concerta®, Equasym®, Medikinet®, Methylfenidaat Sandoz®, Methylphenidate Mylan®, Rilatine®, Provigil®, Xyrem® en Wakix® - notably, this list consists primarily of methylphenidate-based medications, not amphetamines.\n\n**Limited Evidence of Amphetamine Availability:**\nWhile a market report mentions amphetamine, dextroamphetamine, and lisdexamfetamine in Belgium's ADHD market analysis, and some Belgian university students reported using amphetamines or dextroamphetamine, this appears to be very limited. One study noted that twelve subjects reported using amphetamines or dextroamphetamine out of over 12,000 surveyed students.\n\n**Regulatory Context:**\nMedicines for the treatment of ADHD (e.g. medicines containing the active substance methylphenidate) are mentioned in Belgium's narcotic substances regulations, but amphetamines are not specifically listed in the travel documentation, suggesting they may not be widely prescribed there.\n\n**Practical Reality:**\nThink of Belgium's ADHD medication landscape like a restaurant with a limited menu - while other countries might offer the full spectrum of both methylphenidate and amphetamine-based options, Belgium appears to focus heavily on methylphenidate-based treatments. This creates a situation where patients seeking amphetamine-based treatments might face significant challenges in accessing them, and reimbursement is even more limited (with adults receiving no reimbursement at all for ADHD medications).\n\nIf you're specifically looking for amphetamine-based ADHD medications in Belgium, I'd recommend consulting directly with Belgian healthcare providers or the FAMHP, as the availability appears to be very restricted compared to countries like the US where these medications are more commonly prescribed.",
      "created_at": "2025-05-28T11:05:37.611405Z",
      "sequence_order": 1,
      "metadata": {
        "content": [
          {
            "start_timestamp": "2025-05-28T11:05:02.507808Z",
            "stop_timestamp": "2025-05-28T11:05:02.991322Z",
            "flags": null,
            "type": "text",
            "text": " I'll search for current information about amphetamine-based ADHD medications available in Belgium.",
            "citations": []
          },
          {
            "start_timestamp": "2025-05-28T11:05:03.322769Z",
            "stop_timestamp": "2025-05-28T11:05:03.987063Z",
            "flags": null,
            "type": "tool_use",
            "name": "web_search",
            "input": {
              "query": "amphetamine ADHD medications Belgium available 2025"
            },
            "message": "Searching the web",
            "integration_name": null,
            "integration_icon_url": null,
            "context": null,
            "display_content": null,
            "approval_options": null,
            "approval_key": null
          },
          {
            "start_timestamp": null,
            "stop_timestamp": null,
            "flags": null,
            "type": "tool_result",
            "name": "web_search",
            "content": [
              {
                "type": "knowledge",
                "title": "Information for travellers | FAMHP",
                "url": "https://www.famhp.be/en/human_use/particular_products/specially_reglemented_substances/narcotics_psychotropics/informations_pour_les_voyageurs",
                "metadata": {
                  "type": "webpage_metadata",
                  "site_domain": "famhp.be",
                  "favicon_url": "https://www.google.com/s2/favicons?sz=64&domain=famhp.be",
                  "site_name": "Famhp"
                },
                "is_missing": false,
                "text": "If you are travelling and your medicine contains a substance referred to in the Royal Decree of 06/09/2017 regulating narcotic and psychotropic substances, you will need an official accompanying document proving that you were prescribed these medicines as part of a medical treatment.\n\nMedicines for the treatment of ADHD (e.g. medicines containing the active substance methylphenidate); Medicines used in substitution therapy (e.g. methadone, buprenorphine). ... The Schengen area consists of 27 countries: Austria, Belgium, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Italy, Latvia, Liechtenstein, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Slovakia, Slovenia, Spain, Sweden and Switzerland. More information · If you travel to one of these countries and take a medicine containing narcotic or psychotropic substances, you must send this form (in Dutch or in French) at least twenty working days (four weeks) in advance to: Federal Agency for Medicines and Health Products DG Inspection - Authorisations Division - Narcotics Team Avenue Galilée 5/03 1210 Brussels ·\n\nIn this way, your medical treatment can be followed up correctly. It is forbidden to have narcotic or psychotropic substances sent to you from Belgium. After validation of the fully and correctly completed form, the document will be sent by post to the person concerned. Take the approved declaration with you when you travel and keep it with your medicines. Show the declaration when asked. The FAMHP is only competent for validating Schengen declarations of medicines containing narcotic or psychotropic substances for citizens domiciled in Belgium who must take these medicines with them during their journey to a country within the Schengen area. We do not validate documents for other medicines, citizens domiciled abroad or travels to countries outside the Schengen area. Travellers to Spain must also obtain a \"Permiso de Viajeros\" according to Spain's national legislation.\n\nThe application can be submitted through the Spanish embassy in Belgium. Medicinal cannabis (dry buds) containing tetrahydrocannabinol: dispensing this type of product in Belgium is prohibited by the Royal Decree of 11 June 2015 regulating products containing one or more tetrahydrocannabinols. As a public service, we cannot validate a Schengen declaration for a product whose dispensing is prohibited in Belgium. If you use medicines as part of a substitution therapy (e.g. methadone, buprenorphine), always check the information of the country you are travelling to on the INCB website or contact the embassy of your travel destination. Such medicines are often subject to stricter rules or special procedures. Travelling outside the Schengen area No agreements have been concluded with countries outside the Schengen area on the bringing along of medicines containing narcotic or psychotropic substances.\n\nIf a medical certificate is required to be legalised by public authorities, you can contact the FPS Health, Food Chain Safety and Environment for more information. Travelling to Belgium A traveller who needs to bring along narcotic or psychotropic substances into Belgium as part of a medical treatment must be able to justify this by means of a valid medical prescription or a certificate validated by public authorities, such as the Schengen declaration. The maximum amount of medicines brought along to Belgium may not exceed a treatment duration of 3 months. If your travel lasts longer than 30 days and this is the limit of the country of origin or your travel takes longer than 3 months, you should contact a doctor in Belgium. In this way, your medical treatment can be followed up correctly. It is forbidden to have narcotic or psychotropic substances sent to Belgium.",
                "is_citable": true,
                "prompt_context_metadata": {
                  "url": "https://www.famhp.be/en/human_use/particular_products/specially_reglemented_substances/narcotics_psychotropics/informations_pour_les_voyageurs"
                }
              },
              {
                "type": "knowledge",
                "title": "Taking stimulants abroad - ADxS.org",
                "url": "https://www.adxs.org/en/page/458/taking-stimulants-abroad",
                "metadata": {
                  "type": "webpage_metadata",
                  "site_domain": "adxs.org",
                  "favicon_url": "https://www.google.com/s2/favicons?sz=64&domain=adxs.org",
                  "site_name": "Adxs"
                },
                "is_missing": false,
                "text": "Stimulants (methylphenidate / MPH and amphetamine medication / AMP) are legally narcotics (BtM) in Germany (along with many other substances).1 This article deals with the regulations for importing these stimulants from Germany and for possession in other countries.\n\nIn the case of criminal proceedings based on national law concerning the medically necessary and permissible use of medication (which, as in the case of ADHD, increases road safety), it would have to be examined on a case-by-case basis whether the national provisions applied violate higher-ranking European law. Information from the Czech Ministry of the Interior confirmed that any detection of amphetamines in the blood could result in criminal proceedings and the loss of a driver’s license. Lisdexamfetamine has been on the Czech list of BTMs, which prohibits driving a motor vehicle, since 2017. Methylphenidate is also affected. Land Transportation Act, PART ONE TITLE VI, § 125c · “The substances are on the list of narcotics and psychotropic substances (Government Decree No. 463/2013, List No. 5). The driver may not drive a motor vehicle immediately after taking or under the influence of these substances.”4 ·\n\nThe Czech Ministry of Health is aware that the active ingredient is used as a medication for ADHD. However, lisdexamfetamine is not available in the Czech Republic and no approval is planned. We assume that this is even more likely to apply to attentin or amphetamine salts. ... The laws in the Czech Republic, Estonia, Poland, Slovenia and Slovakia penalize driving with any trace of a substance, even if it is a drug.5 ... The laws in the Czech Republic, Estonia, Poland, Slovenia and Slovakia penalize driving with any trace of a substance, even if it is a drug.5 ... The laws in the Czech Republic, Estonia, Poland, Slovenia and Slovakia penalize driving with any trace of a substance, even if it is a drug.5 ... The laws in the Czech Republic, Estonia, Poland, Slovenia and Slovakia penalize driving with any trace of a substance, even if it is a drug.5 ...\n\nCertificates issued by a doctor or hospital or prescriptions prescribed by a doctor are acceptable in this context. It is also recommended to have a Schengen certificate issued by a doctor (the Schengen certificate does not need to be notarized by the health authorities). At the same time, please note that you may only import the quantity of medicines and tablets that you actually need during your stay in Turkey. It is important to note that there must be no suspicion of commercial trade in the products. *The importation of cannabis, marijuana and hemp in the form of flower, including for use as medicine, is not permitted.”* According to information from the US Embassy in Berlin and the responsible health department dated 24.01.2025 is required: A certificate (in English) stating that the medication is being taken on an ongoing basis for medical reasons.\n\nStimulants (methylphenidate / MPH and amphetamine medication / AMP) are legally narcotics (BtM) in Germany (along with many other substances).1 This article deals with the regulations for importing these stimulants from Germany and for possession in other countries. A further description can be found at the Federal Institute for Drugs and Medical Devices (BfArM) at Traveling with narcotics. 1. Carrying stimulants when traveling to countries in the Schengen Agreement · 2. Travel to countries outside the Schengen Agreement ... When traveling to EU countries that are members of the Schengen Agreement, narcotics that have been acquired on the basis of a medical prescription may be imported and exported as travel requirements in the quantity required for the duration of the trip. For this purpose, a certificate completed by a doctor for the carrying of narcotics in the context of medical treatment in accordance with Article 75 of the Schengen Implementation Agreement Must be carried.",
                "is_citable": true,
                "prompt_context_metadata": {
                  "url": "https://www.adxs.org/en/page/458/taking-stimulants-abroad"
                }
              },
              {
                "type": "knowledge",
                "title": "Belgium Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Report 2022 to 2030",
                "url": "https://www.insights10.com/report/belgium-adhd-attention-deficit-hyperactivity-disorder-therapeutic-market-analysis/",
                "metadata": {
                  "type": "webpage_metadata",
                  "site_domain": "insights10.com",
                  "favicon_url": "https://www.google.com/s2/favicons?sz=64&domain=insights10.com",
                  "site_name": "Insights10"
                },
                "is_missing": false,
                "text": "Belgium&#x27;s attention deficit hyperactivity disorder therapeutics market is expected to witness growth from $65 Mn in 2022 to $116 Mn in 2030 with a CAGR of 7.5% for the year 2022-30.\n\nBelgium's Attention Deficit Hyperactivity Disorder (ADHD) therapeutics market is expected to witness growth from $65 Mn in 2022 to $116 Mn in 2030 with a CAGR of 7.5% for the year 2022-2030 due to factors like rising cases of ADHD among the Belgian population and the improved health expenditure for greater access to ADHD medications. The Belgium ADHD therapeutics market is segmented by drug, drug type, demographics, and by distribution channel. Some of the major players in the market include Celyad, Confo Therapeutics, and Advanz Pharmaceuticals. ID: IN10BEPH028 CATEGORY: Pharmaceuticals GEOGRAPHY: Belgium AUTHOR: Parul Choudhary ... The Belgium Attention Deficit Hyperactivity Disorder (ADHD) therapeutics market size is at around $65 Mn in 2022 and is projected to reach $116 Mn in 2030, exhibiting a CAGR of 7.5% during the forecast period. In order to cover higher utility bills, the hospital industry in Belgium will receive $85.43 Mn in the first half of 2023.\n\nMost often, symptoms appear before the age of seven. According to a study by the Belgian Health Care Knowledge Centre (KCE) that was released in 2022, children and adolescents in Belgium between the ages of 6 and 17 are thought to have an ADHD prevalence of about 5.5%. No matter the patient's age, the High Council for Health (SHC) in Belgium emphasizes that the first course of treatment should be psycho-educative therapy, which also involves the patient's family and community. Other approaches should only be contemplated when that fails. Methylphenidate, better known by its brand name Ritalin, is currently the only ADHD drug that is reimbursed in Belgium for patients under the age of 18. Adults are not at all reimbursed by typical medical insurance. Non-drug therapies are either not adequately accessible in Belgium or are too expensive for many families to afford due to cost-reimbursement policies.\n\nAs the prevalence of ADHD rises and more people in Belgium are given the diagnosis, there is increasing demand for ADHD treatments like medication and psychotherapy. To more accurately identify and treat ADHD, breakthroughs in technology are being developed. As healthcare expenditure in Belgium rises, more funds are being directed toward ADHD treatment. This is anticipated to drive the Belgium ADHD therapeutics market's expansion. ... Financial hardships or resource limitations may make it more challenging for patients to receive treatment for ADHD. This may restrict the Belgium ADHD therapeutics market expansion. Some patients may experience negative side effects from their ADHD therapies, which may cause them to discontinue taking it or reduce their desire to take it. This might slow the Belgium ADHD therapeutics market's expansion. ... The Federal Agency for Medicines and Health Products, formerly the Directorate-General for Medicinal Products of the FPS Public Health (Agence Federe\n\nOne of the budgetary measures will release $106.79 Mn as structural cost compensation for conventional healthcare providers—those who adhere to the formal fees set by physicians and healthcare organizations in Belgium. $106.79 Mn will be made available from the health insurance budget, which was unanimously passed, for structural cost compensation for healthcare providers, but only for those who are contracted. The highest co-payment ceilings will also not be indexed. Additional funding for accessible dental care, improved eyewear coverage, and targeted initiatives to improve treatment and quality of life for cancer patients are also planned. The neurological condition known as Attention Deficit Hyperactivity Disorder (ADHD) is frequently affected by genetics. It is marked by impulsivity, restlessness, or hyperactivity. In the setting of primary care, it is the neurodevelopmental disorder with a childhood onset that is most commonly encountered.",
                "is_citable": true,
                "prompt_context_metadata": {
                  "url": "https://www.insights10.com/report/belgium-adhd-attention-deficit-hyperactivity-disorder-therapeutic-market-analysis/"
                }
              },
              {
                "type": "knowledge",
                "title": "European guidelines on managing adverse effects of medication for ADHD - PMC",
                "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3012210/",
                "metadata": {
                  "type": "webpage_metadata",
                  "site_domain": "nih.gov",
                  "favicon_url": "https://www.google.com/s2/favicons?sz=64&domain=nih.gov",
                  "site_name": "Nih"
                },
                "is_missing": false,
                "text": "The safety of ADHD medications is not fully known. Concerns have arisen about both a lack of contemporary-standard information about medications first licensed several decades ago, and signals of possible harm arising from more recently developed ...\n\n17Department of Experimental Clinical and Health Psychology, Ghent University, Ghent, Belgium · 18University of London and Institute of Child Health, University College London, London, UK · 19Child Neuropsychiatry, Department of Neuroscience, University of Cagliari, Cagliari, Italy · 20Department of Child and Adolescent Psychiatry, University of Zürich, Zürich, Switzerland · 21MRC Social Genetic Developmental and Psychiatry Centre, Institute of Psychiatry, London, UK ... Corresponding author. Received 2010 Mar 24; Accepted 2010 Oct 6; Issue date 2011. ... This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. ... The safety of ADHD medications is not fully known.\n\nParadoxical effects of d-amphetamine upon seizure susceptibility in 2 selectively bred lines of mice. Dev Psychobiol. 1980;13:7–15. doi: 10.1002/dev.420130103. [DOI] [PubMed] [Google Scholar] 51.Gross-Tsur V, Manor O, van der, Meere J, Joseph A, Shalev RS. Epilepsy and attention deficit hyperactivity disorder: is methylphenidate safe and effective? J Pediatr. 1997;130:670–674. doi: 10.1016/S0022-3476(97)70258-0. [DOI] [PubMed] [Google Scholar] 52.Gucuyener K, Erdemoglu AK, Senol S, Serdaroglu A, Soysal S, Kockar AI. Use of methylphenidate for attention-deficit hyperactivity disorder in patients with epilepsy or electroencephalographic abnormalities. J Child Neurol. 2003;18:109–112. doi: 10.1177/08830738030180020601. [DOI] [PubMed] [Google Scholar] 53.Halmoy A, Fasmer OB, Gillberg C, Haavik J. Occupational outcome in adult ADHD: impact of symptom profile, comorbid psychiatric problems, and treatment: a cross-sectional study of 414 clinically diagnosed adult ADHD patients.\n\n68.Kessler RC, Adler L, Barkley R, Biederman J, Conners CK, Demler O, Faraone SV, Greenhill LL, Howes MJ, Secnik K, Spencer T, Ustun TB, Walters EE, Zaslavsky AM. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163:716–723. doi: 10.1176/appi.ajp.163.4.716. [DOI] [PMC free article] [PubMed] [Google Scholar] 69.King GA, Burnham WM. Effects of d-amphetamine and apomorphine in a new animal model of petit mal epilepsy. Psychopharmacology (Berl) 1980;69:281–285. doi: 10.1007/BF00433096. [DOI] [PubMed] [Google Scholar] 70.Kinsbourne M. Stimulants for insomnia. N Engl J Med. 1973;288:1129. doi: 10.1056/NEJM197305242882121. [DOI] [PubMed] [Google Scholar] 71.Klein RG, Landa B, Mattes JA, Klein DF. Methylphenidate and growth in hyperactive children. A controlled withdrawal study.\n\n74.Kratochvil C, Vaughan BS, Mayfield-Jorgensen ML, March J, Kollins S, Ravi H, Greenhill L, Kotler L, Paykina MA, Biggins BA, Stoner J (2006) A Pilot study of atomoxetine in young children with ADHD [DOI] [PubMed] 75.Krzyzaniak A, Krzywinska-Wiewiorowska M, Stawinska-Witoszynska B, Kaczmarek M, Krzych L, Kowalska M, Szilagyi-Pagowska I, Palczewska I, Karch A, Josko J, Ostrowska-Nawarycz L, Nawarycz T. Blood pressure references for Polish children and adolescents. Eur J Pediatr. 2009;168:1335–1342. doi: 10.1007/s00431-009-0931-2. [DOI] [PubMed] [Google Scholar] 76.Laurelle MD, Abi-Dargham A, van Dyck CH. Single photon emission computerised tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA. 1996;93:9235–9240. doi: 10.1073/pnas.93.17.9235. [DOI] [PMC free article] [PubMed] [Google Scholar] 77.Ledbetter M.",
                "is_citable": true,
                "prompt_context_metadata": {
                  "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3012210/"
                }
              },
              {
                "type": "knowledge",
                "title": "ADHD Medications: How They Work & Side Effects",
                "url": "https://my.clevelandclinic.org/health/treatments/11766-adhd-medication",
                "metadata": {
                  "type": "webpage_metadata",
                  "site_domain": "clevelandclinic.org",
                  "favicon_url": "https://www.google.com/s2/favicons?sz=64&domain=clevelandclinic.org",
                  "site_name": "Cleveland Clinic"
                },
                "is_missing": false,
                "text": "ADHD medication treats the symptoms of attention-deficit/hyperactivity disorder. They work by increasing the levels of certain neurotransmitters in your brain.\n\nExtended-release (intermediate-acting or long-acting): You typically take these stimulants once in the morning each day. Some last from six to eight hours, while others last for up to 16 hours. Longer-acting ADHD medications may result in fewer “ups and downs” during the day and may reduce the need for extra doses at school or during work. Many people supplement an extended-release medication taken in the morning with an immediate-release dose taken in the mid to late afternoon. This extra dose may help cover the late afternoon to evening hours after the earlier dose starts to wear off. Most stimulants fall into one of two drug classes: methylphenidates or amphetamines. Drug classifications group medications together by their similarities, such as active ingredients or approved use. ... Non-stimulants are prescription medications, but they’re not controlled substances like stimulants.\n\nADHD medication treats the symptoms of attention-deficit/hyperactivity disorder (ADHD), such as hyperactivity and impulsivity. ADHD medications work by increasing the levels of chemicals (neurotransmitters) in your brain. It can take time to find the right ADHD medication for you, but once you do, you’ll likely see an improvement in your symptoms. ... Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy ... ContentsOverviewRisks / BenefitsRecovery and OutlookWhen To Call the DoctorAdditional Common Questions · For many people, putting on eyeglasses helps them focus their eyes. In the same way, ADHD medication helps people with ADHD focus their thoughts. The medications help them ignore distractions, pay attention and control their behavior.\n\nMedication doesn’t cure ADHD. But it can help ease the symptoms of ADHD while you or your child is taking it so you can function more effectively. ... Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy · The U.S. Food and Drug Administration (FDA) has approved several different kinds of medications to treat ADHD. Many of the medications can treat ADHD in children as young as 6. Attention-deficit/hyperactivity disorder (ADHD) is a very common neurodevelopment disorder. Children with the disorder may be overly active and have trouble with impulsive behaviors. They may also find it difficult to pay attention, follow instructions and complete tasks. When symptoms of ADHD occur during childhood, they frequently continue into adulthood.\n\nOne study suggested ADHD symptoms carried into adulthood in 90% of cases. In addition, some adults with ADHD haven’t ever been diagnosed. Adults with ADHD may have trouble following directions, remembering information, concentrating or organizing tasks. Symptoms may look different for adults than they do for children. For instance, hyperactivity in children may appear as extreme restlessness in adults. ADHD medications work in different ways depending on the type. But all ADHD medications work by increasing the levels of important chemicals (neurotransmitters) in your brain. These neurotransmitters include dopamine and norepinephrine. Increasing the amount of these neurotransmitters helps improve the symptoms of ADHD, including: ... Increasing attention span. Reducing hyperactivity. Controlling impulsive behavior. Managing executive dysfunction.",
                "is_citable": true,
                "prompt_context_metadata": {
                  "age": "September 8, 2023",
                  "url": "https://my.clevelandclinic.org/health/treatments/11766-adhd-medication"
                }
              },
              {
                "type": "knowledge",
                "title": "1 in 20 university students uses stimulant medicines in order to study better | FAMHP",
                "url": "https://www.famhp.be/en/news/1_in_20_university_students_uses_stimulant_medicines_in_order_to_study_better",
                "metadata": {
                  "type": "webpage_metadata",
                  "site_domain": "famhp.be",
                  "favicon_url": "https://www.google.com/s2/favicons?sz=64&domain=famhp.be",
                  "site_name": "Famhp"
                },
                "is_missing": false,
                "text": "Stimulant medicines containing methylphenidate, modafinil, pitolisant and atmoxetine (list of medicines that are commercialised in Belgium) are approved for the treatment of attention deficit and disorder with or without hyperactivity (ADD/ADHD) and narcolepsy. These are prescription medicines. Abuse can lead to healthproblems such as heart problems, elevated blood pressure, insomnia, depression, panic attacks and addiction. ... Some students use stimulants in the hope of improving their study performance. In Flanders, regular surveys are being performed in order to investigate drug use and the use of stimulant medicines in students. For francophone universities in Belgium there were no data. Therefore, the Department of Vigilance of the FAMHP performed a survey for these students. The survey was performed in October and November 2018 at six francophone universities in Belgium.\n\nFurther information Reporting abuse or misuse of medicines (Dutch or French only) Educational material on methylphenidate (Dutch only) Studies and medication in Flanders campaign (Dutch only) ADHD Health Care Path (Dutch or French only) FAMHP campaigns Een geneesmiddel is geen snoepje. Geneesmiddelen via internet? Surf niet met uw gezondheid! Commercialised stimulant medicines in Belgium Concerta®, Equasym®, Medikinet®, Methylfenidaat Sandoz®, Methylphenidate Mylan®, Rilatine®, Provigil®, Xyrem® en Wakix®\n\nBetter concentration while studying, being able to study longer and improving study performance were by far the most significant reasons why these medicines are used. Using them as a party drug or for weight loss, however, is rather rare. The use of stimulant medicines is more frequent during the revision and exam period. While most medical users take these medicines at least on a weekly basis, non-medical users take them more sporadically. Users notice side effects. In both medical and non-medical users of stimulant drugs, the most frequently reported negative effects were sleep disorders, heart palpitations and emotional instability. In general, stimulant medicines are commonly associated with headache, nervousness, agitation, decrease in appetite, nausea and stomach ache. Generally speaking, the intensity of these side effects rises as used doses increase.\n\nStimulant medicines for non-medical use are mostly acquired via friends and acquaintances. Friends or acquaintances within and outside of the student community are the most significant source of stimulant medicines for non-medical use. This suggests some patients in medical treatment are sharing their medicines with their friends. 8% of non-medical users acquired these medicines via illegal online channels. Numbers are in line with those of other studies. A European overview study from 2015 shows 1% to 16% of students taking stimulant medicines for non-medical use. Flemish university and college students report a non-medical use of 9% in 2017. The design and execution of these studies, however, were different. Therefore, results of the new survey cannot be directly compared to those of these previous studies. From research by the socialist mutualities in 2018 it appeared that Flemish youngsters use more stimulant medicines than their counterparts in Wallonia or Brussels.",
                "is_citable": true,
                "prompt_context_metadata": {
                  "url": "https://www.famhp.be/en/news/1_in_20_university_students_uses_stimulant_medicines_in_order_to_study_better"
                }
              },
              {
                "type": "knowledge",
                "title": "Upcoming ADHD Medications: What to Expect in 2025 - Spark Mental Health",
                "url": "https://www.sparkmentalhealth.com/upcoming-adhd-medications-what-to-expect-in-2025/",
                "metadata": {
                  "type": "webpage_metadata",
                  "site_domain": "sparkmentalhealth.com",
                  "favicon_url": "https://www.google.com/s2/favicons?sz=64&domain=sparkmentalhealth.com",
                  "site_name": "Spark Mental Health"
                },
                "is_missing": false,
                "text": "Explore new ADHD medications in 2025, their benefits, and expert insights to stay informed about the latest treatment options.\n\nThe landscape of ADHD medications is evolving rapidly, with new ADHD medications in 2025 promising improved efficacy and fewer side effects. These advancements could revolutionize how we manage ADHD symptoms and enhance the quality of life for millions of individuals worldwide. The ADHD medication market currently features two primary classes: stimulants and non-stimulants. Stimulants, including methylphenidate and amphetamines, serve as the first-line treatment for many patients. These medications increase dopamine levels in the brain, which improves focus and reduces hyperactivity. Non-stimulants, such as atomoxetine and guanfacine, provide an alternative for individuals who don’t respond well to stimulants or have contraindications. Current ADHD medications, while effective for many, present significant drawbacks. Side effects remain a major concern, with appetite suppression, sleep disturbances, and mood changes frequently reported.\n\nThe landscape of ADHD treatment will transform significantly by 2025. New ADHD medications in 2025 will offer more effective symptom management with fewer side effects. These advancements include innovative non-stimulant approaches, novel delivery methods, and promising combination therapies that will revolutionize patient care. Healthcare providers will have greater flexibility to tailor treatment plans to individual patient needs as more options become available. This personalized approach, combined with improved medication adherence, has the potential to enhance outcomes for individuals with ADHD. Patients, caregivers, and healthcare professionals must stay informed about these emerging treatment options to make informed decisions about ADHD management. Spark Mental Health provides personalized, evidence-based care for individuals with ADHD and other mental health conditions.\n\nResearchers explore innovative ways to deliver existing ADHD medications more effectively. A transdermal patch for methylphenidate aims to provide steady medication release over 24 hours. The DAYTRANA patch is a long-acting ADHD treatment that can be removed early to fit a child’s individual needs. An inhaled form of amphetamine is also under investigation. This rapid-onset formulation could offer more flexible dosing options, potentially allowing patients to manage symptoms as needed throughout the day. Early data suggests onset of action within 10-15 minutes (compared to 30-60 minutes for oral medications). The concept of combining different medications to target multiple aspects of ADHD gains traction. A notable trial investigates the synergistic effects of a stimulant medication with a non-stimulant alpha-2 agonist. Preliminary results indicate this combination may provide more comprehensive symptom control while allowing for lower doses of each medication, potentially reducing sid\n\nAnother intriguing study explores the combination of ADHD medication with a cognitive enhancer typically used in Alzheimer’s treatment. This approach aims to address not only core ADHD symptoms but also associated cognitive deficits that can persist even with traditional ADHD treatment. Interestingly, a recent study suggests that adult ADHD is associated with an increased risk of dementia, highlighting the importance of reliable assessment in adulthood. While these developments show promise, it’s important to note that not all medications in clinical trials will reach the market. The FDA approval process remains rigorous, ensuring safety and efficacy before any new treatment becomes available. As research progresses, the potential benefits of these new medications become clearer. The next chapter will explore how these innovations might improve the lives of individuals with ADHD and transform the landscape of ADHD management.",
                "is_citable": true,
                "prompt_context_metadata": {
                  "age": "February 23, 2025",
                  "url": "https://www.sparkmentalhealth.com/upcoming-adhd-medications-what-to-expect-in-2025/"
                }
              },
              {
                "type": "knowledge",
                "title": "ADHD medicine consumption in Europe after COVID-19: catch-up or trend change? | BMC Psychiatry | Full Text",
                "url": "https://bmcpsychiatry.biomedcentral.com/articles/10.1186/s12888-024-05505-9",
                "metadata": {
                  "type": "webpage_metadata",
                  "site_domain": "biomedcentral.com",
                  "favicon_url": "https://www.google.com/s2/favicons?sz=64&domain=biomedcentral.com",
                  "site_name": "Biomedcentral"
                },
                "is_missing": false,
                "text": "Only in five countries ADHD medicine sales were below the predictions. Belgium (-9%), Slovakia (-6%), the Czech Republic (-4%), Romania (-16%), and Italy (-6%). These countries were also among those most negatively impacted in 2020 and 2021. Throughout Europe, the consumption in 2022 was predicted ...\n\nAlthough the COVID-19 pandemic and its implications have been associated with mental health services utilization and medication consumption, there is no longitudinal study on the long-term impact on ADHD medication use trends. This study examines the European ADHD medication consumption in 2020 to 2022 compared to the predicted consumption assuming the persistence of pre-pandemic trends. Predictions are calculated using Seasonal Autoregressive Integrated Moving Average (SARIMA) models. While European ADHD medication sales recorded a drop in 2020, they returned to the predicted level in 2021, even slightly exceeding it. In 2022, we found a clear exceedance of the predicted level by 16.4% on average at country level. Furthermore, the increase in consumption growth in the post-pandemic period (2021–2022) compared to the pre-pandemic period (2014–2019) was significant in 26 of the 28 European countries under consideration.\n\nBackground Although the COVID-19 pandemic and its implications have been associated with mental health services utilization and medication consumption, there is no longitudinal study on the long-term impact on ADHD medication use trends. Methods This study examines the European ADHD medication consumption in 2020 to 2022 compared to the predicted consumption assuming the persistence of pre-pandemic trends. Predictions are calculated using Seasonal Autoregressive Integrated Moving Average (SARIMA) models. Results While European ADHD medication sales recorded a drop in 2020, they returned to the predicted level in 2021, even slightly exceeding it. In 2022, we found a clear exceedance of the predicted level by 16.4% on average at country level. Furthermore, the increase in consumption growth in the post-pandemic period (2021–2022) compared to the pre-pandemic period (2014–2019) was significant in 26 of the 28 European countries under consideration.\n\nNon-significant increases were observed in Belgium and Croatia (Table 4). Throughout Europe (Fig. 2), the pre-pandemic regression slope was estimated as 0.03 (p < 0.001), increasing to 0.11 (p < 0.001) in the post-pandemic period. The latter is significantly larger than the former (p < 0.001). The individual-country analogues of Fig. 2 can be found the Supplement (Figure S2). Table 4 Estimated parameters by linear regressions, and t-test p-values testing post-pandemic < = pre-pandemic ... Quarterly ADHD consumption in Europe. Regression line in pre COVID years (2014–2019) is marked as red line, in post COVID years (2021–2022) as green line. DDD = defined daily dose ... For each country and for Europe in total, we calculated the difference between the actual ADHD medication consumption for the period from 2020 to 2022 and the predicted consumption under non-pandemic conditions.\n\n4). In 23 of the 28 countries, the actual ADHD medication consumption was higher than predicted; in ten countries consumption surpassed predictions by more than 20%. The average relative deviation revealed a mean exceedance of national consumption forecasts by 16.4% in 2022. Only in five countries ADHD medicine sales were below the predictions. Belgium (-9%), Slovakia (-6%), the Czech Republic (-4%), Romania (-16%), and Italy (-6%). These countries were also among those most negatively impacted in 2020 and 2021. Throughout Europe, the consumption in 2022 was predicted as 3.08 DDD per 1000 inhabitants per day without the emergence of COVID-19, whereas the actual consumption amounted to 3.43 DDD per 1000 inhabitants per day, which corresponds to an increase of 11.5%. Comparing the mean national (unweighted averages) relative differences per quarter (Fig.",
                "is_citable": true,
                "prompt_context_metadata": {
                  "url": "https://bmcpsychiatry.biomedcentral.com/articles/10.1186/s12888-024-05505-9"
                }
              },
              {
                "type": "knowledge",
                "title": "Know Before You Go: International Travel with ADHD Medications - CHADD",
                "url": "https://chadd.org/adhd-weekly/know-before-you-go-international-travel-with-adhd-medications/",
                "metadata": {
                  "type": "webpage_metadata",
                  "site_domain": "chadd.org",
                  "favicon_url": "https://www.google.com/s2/favicons?sz=64&domain=chadd.org",
                  "site_name": "CHADD"
                },
                "is_missing": false,
                "text": "Do you plan to travel out of the United States, either for business or on vacation? Before you go, you need to reach out to both the US Department of State and the embassy of the country you plan to visit if you intend to take your ADHD medication with you. “Travelers should not assume…\n\nBefore you go, you need to reach out to both the US Department of State and the embassy of the country you plan to visit if you intend to take your ADHD medication with you. “Travelers should not assume that medications approved in the US are approved in another country,” the State Department advises. “At least two months before departure, the traveler should consult with the treating physician about specific medications and obtain a list of comparable, generic names, including their dosage and composition, in case there is a need for a refill if the medication is licensed.” ... The State Department describes the situation of a US citizen who was arrested while visiting Japan after her stimulant medication was shipped to her there. She had requested the medication be repackaged in the hope of protecting her privacy. Her prescription Adderall, which is an amphetamine, is not legal in Japan.\n\nJoin the discussion: Have your traveled to another country with your ADHD medication? What was your experience? Know Before You Go: International Travel with ADHD Medications ·\n\nStudy Shows Omega-3s Benefit Some Children With ADHD",
                "is_citable": true,
                "prompt_context_metadata": {
                  "age": "August 10, 2022",
                  "url": "https://chadd.org/adhd-weekly/know-before-you-go-international-travel-with-adhd-medications/"
                }
              },
              {
                "type": "knowledge",
                "title": "Use and misuse of prescription stimulants by university students: a cross-sectional survey in the french-speaking community of Belgium, 2018 | Archives of Public Health | Full Text",
                "url": "https://archpublichealth.biomedcentral.com/articles/10.1186/s13690-022-00816-3",
                "metadata": {
                  "type": "webpage_metadata",
                  "site_domain": "biomedcentral.com",
                  "favicon_url": "https://www.google.com/s2/favicons?sz=64&domain=biomedcentral.com",
                  "site_name": "Biomedcentral"
                },
                "is_missing": false,
                "text": "The following drugs, marketed in Belgium at the time of the survey, were listed : MPH, modafinil, atomoxetine, guanfacine, and sodium oxybate. The latter three drugs, although not considered stimulants, can also be potentially misused for similar purposes as PS.\n\nMisuse of prescription stimulants (PS) has been reported among students to enhance academic performance in Flanders (Belgium). However, PS misuse among students in the French-speaking community is unknown. The main purpose of the study was to estimate the prevalence of medical use and misuse of PS by university students in the French-speaking community (Belgium), and to investigate the reasons and sources associated with PS misuse. A cross-sectional online survey was performed in 2018. All university students 18 years and older were invited to participate and asked about PS use, including medical (i.e., used for therapeutic purposes) and nonmedical reasons and sources of PS. In total, 12 144 students participated in the survey (median age = 21 years, 65.5% female). The estimated prevalence of PS use was 6.9% (ever use) and 5.5% (past-year). Among ever users, 34.7% were classified as medical users and 65.3% as misusers.\n\nThe first section of the questionnaire was designed to collect data about use of ADHD and narcolepsy medication. The following drugs, marketed in Belgium at the time of the survey, were listed : MPH, modafinil, atomoxetine, guanfacine, and sodium oxybate. The latter three drugs, although not considered stimulants, can also be potentially misused for similar purposes as PS. An additional free-text option was presented for other possible medications. Since this article focuses on the use and misuse of PS, we selected MPH and modafinil (referred to as PS in this article) for further analysis because these are psychostimulants or have stimulant-like effects. Additional questions collected data on sociodemographic variables (gender, age, study year, working and housing status) and use of other substances (such as alcohol, nicotine, energy drinks, hypnotics, sedatives, corticosteroids, cannabis, amphetamines, ecstasy or cocaine).\n\nAmong PS users, 277 (34.7%, 95% CI 31.4%-38.1%) were classified as medical users and 522 (65.3%, 95%CI 62.0-68.6%) as misusers. The prevalence of lifetime misuse in the overall study population was 4.5% (95%CI 4.1-4.9%). Among medical users, 26 subjects (9.5%, 95%CI 6.2-13.6%) reported to have used PS also for other purposes. Of the PS users, 763 subjects (95.0%) and 81 subjects (10.1%) reported using MPH and modafinil, respectively. Other reported drugs were: atomoxetine (n=38), oxybate (n=34) and guanfacine (n=30). Sixty subjects reported use of other drugs, including 12 subjects who reported using amphetamines or dextroamphetamine. The prevalence of PS use was higher among those who responded only partially to the questionnaire (13.8%, 95%CI 12.0-15.9%) compared to those who responded to all questions (6.1%, 95%CI 5.6-6.6%). The majority of the medical users reported using PS for the treatment of attention disorder (n=238, 85.9%, 95% CI 81.3%-89.8%).\n\nWe found that lifetime use was twice as high in males as in females and increased with age, confirming trends observed in other studies [2, 22, 23]. It should be noted, however, that there is no significant gender difference in the diagnosis of ADHD in adulthood, in contrast to childhood when the prevalence is higher in boys [24]. Among students using PS for medical reasons, attention deficit disorder was the most frequently cited indication. In our study, the primary reasons for PS misuse were academically related, which is consistent with a review study in which academic motivations were cited by 50–89% of students [5]. While in that study the second most commonly cited reason for non-medical use was “to get high”, we found that misuse as a party drug was rather limited. Furthermore, while there are cases of ADHD with apparent onset in adulthood, it is likely that many of these cases were not previously diagnosed [25]. It is therefore possible that some students are treating themselv",
                "is_citable": true,
                "prompt_context_metadata": {
                  "url": "https://archpublichealth.biomedcentral.com/articles/10.1186/s13690-022-00816-3"
                }
              },
              {
                "type": "text",
                "text": "<system>You only have 19 searches left this turn</system>\n\n",
                "uuid": "70dd581d-000d-43e1-bc6d-4eb6facdc891"
              }
            ],
            "is_error": false,
            "message": null,
            "integration_name": null,
            "integration_icon_url": null,
            "display_content": null
          },
          {
            "start_timestamp": "2025-05-28T11:05:08.376029Z",
            "stop_timestamp": "2025-05-28T11:05:08.711487Z",
            "flags": null,
            "type": "text",
            "text": "\n\nLet me search more specifically for amphetamine-based medications available in Belgium.",
            "citations": []
          },
          {
            "start_timestamp": "2025-05-28T11:05:09.137442Z",
            "stop_timestamp": "2025-05-28T11:05:10.022897Z",
            "flags": null,
            "type": "tool_use",
            "name": "web_search",
            "input": {
              "query": "\"amphetamine\" \"dextroamphetamine\" \"lisdexamfetamine\" Belgium ADHD available"
            },
            "message": "Searching the web",
            "integration_name": null,
            "integration_icon_url": null,
            "context": null,
            "display_content": null,
            "approval_options": null,
            "approval_key": null
          },
          {
            "start_timestamp": null,
            "stop_timestamp": null,
            "flags": null,
            "type": "tool_result",
            "name": "web_search",
            "content": [
              {
                "type": "knowledge",
                "title": "Belgium Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Report 2022 to 2030",
                "url": "https://www.insights10.com/report/belgium-adhd-attention-deficit-hyperactivity-disorder-therapeutic-market-analysis/",
                "metadata": {
                  "type": "webpage_metadata",
                  "site_domain": "insights10.com",
                  "favicon_url": "https://www.google.com/s2/favicons?sz=64&domain=insights10.com",
                  "site_name": "Insights10"
                },
                "is_missing": false,
                "text": "Belgium&#x27;s attention deficit hyperactivity disorder therapeutics market is expected to witness growth from $65 Mn in 2022 to $116 Mn in 2030 with a CAGR of 7.5% for the year 2022-30.\n\nAmphetamine · Methylphenidate · Dextroamphetamine · Dexmethylphenidate · Lisdexamfetamine · Others  · Non-Stimulants · Atomoxetine · Bupropion · Guanfacine · Clonidine · By Age Group (Revenue, USD Billion): Pediatric And Adolescent · Adult · By Distribution Channel (Revenue, USD Billion): Hospital Pharmacies · Speciality Clinics · Retail Pharmacies · e-Commerce · By Psychotherapy (Revenue, USD Billion): Behaviour Therapy · Cognitive Behavioral Therapy · Interpersonal Psychotherapy · Family Therapy · Methodology for Database Creation · Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.​ ·\n\nBelgium's Attention Deficit Hyperactivity Disorder (ADHD) therapeutics market is expected to witness growth from $65 Mn in 2022 to $116 Mn in 2030 with a CAGR of 7.5% for the year 2022-2030 due to factors like rising cases of ADHD among the Belgian population and the improved health expenditure for greater access to ADHD medications. The Belgium ADHD therapeutics market is segmented by drug, drug type, demographics, and by distribution channel. Some of the major players in the market include Celyad, Confo Therapeutics, and Advanz Pharmaceuticals. ID: IN10BEPH028 CATEGORY: Pharmaceuticals GEOGRAPHY: Belgium AUTHOR: Parul Choudhary ... The Belgium Attention Deficit Hyperactivity Disorder (ADHD) therapeutics market size is at around $65 Mn in 2022 and is projected to reach $116 Mn in 2030, exhibiting a CAGR of 7.5% during the forecast period. In order to cover higher utility bills, the hospital industry in Belgium will receive $85.43 Mn in the first half of 2023.\n\nOne of the budgetary measures will release $106.79 Mn as structural cost compensation for conventional healthcare providers—those who adhere to the formal fees set by physicians and healthcare organizations in Belgium. $106.79 Mn will be made available from the health insurance budget, which was unanimously passed, for structural cost compensation for healthcare providers, but only for those who are contracted. The highest co-payment ceilings will also not be indexed. Additional funding for accessible dental care, improved eyewear coverage, and targeted initiatives to improve treatment and quality of life for cancer patients are also planned. The neurological condition known as Attention Deficit Hyperactivity Disorder (ADHD) is frequently affected by genetics. It is marked by impulsivity, restlessness, or hyperactivity. In the setting of primary care, it is the neurodevelopmental disorder with a childhood onset that is most commonly encountered.\n\nMost often, symptoms appear before the age of seven. According to a study by the Belgian Health Care Knowledge Centre (KCE) that was released in 2022, children and adolescents in Belgium between the ages of 6 and 17 are thought to have an ADHD prevalence of about 5.5%. No matter the patient's age, the High Council for Health (SHC) in Belgium emphasizes that the first course of treatment should be psycho-educative therapy, which also involves the patient's family and community. Other approaches should only be contemplated when that fails. Methylphenidate, better known by its brand name Ritalin, is currently the only ADHD drug that is reimbursed in Belgium for patients under the age of 18. Adults are not at all reimbursed by typical medical insurance. Non-drug therapies are either not adequately accessible in Belgium or are too expensive for many families to afford due to cost-reimbursement policies.",
                "is_citable": true,
                "prompt_context_metadata": {
                  "url": "https://www.insights10.com/report/belgium-adhd-attention-deficit-hyperactivity-disorder-therapeutic-market-analysis/"
                }
              },
              {
                "type": "knowledge",
                "title": "Lisdexamfetamine - Wikipedia",
                "url": "https://en.wikipedia.org/wiki/Lisdexamfetamine",
                "metadata": {
                  "type": "webpage_metadata",
                  "site_domain": "wikipedia.org",
                  "favicon_url": "https://www.google.com/s2/favicons?sz=64&domain=wikipedia.org",
                  "site_name": "Wikipedia"
                },
                "is_missing": false,
                "text": "Lisdexamfetamine is an inactive prodrug that works after being converted by the body into dextroamphetamine, a central nervous system (CNS) stimulant. Chemically, lisdexamfetamine is composed of the amino acid L-lysine, attached to dextroamphetamine. Lisdexamfetamine was approved for medical use in the United States in 2007 and in the European Union in 2012. In 2022, it was the 69th most commonly prescribed medication in the United States, with more than 9 million prescriptions. It is a Class B controlled substance in the United Kingdom, a Schedule 8 controlled drug in Australia, and a Schedul\n\nA dose of 50 mg of lisdexamfetamine dimesylate is approximately equimolar to a 20 mg dose of dextroamphetamine sulfate or to 15 mg dextroamphetamine free-base in terms of the amount of dextroamphetamine contained. Lisdexamfetamine capsules can be swallowed intact, or they can be opened and mixed into water, yogurt, or applesauce and consumed in that manner. Pharmaceutical lisdexamfetamine is contraindicated in people with hypersensitivity to amphetamine products or any of the formulation's inactive ingredients. It is also contraindicated in patients who have used a monoamine oxidase inhibitor (MAOI) within the last 14 days. Amphetamine products are contraindicated by the United States Food and Drug Administration (USFDA) in people with a history of drug abuse, heart disease, or severe agitation or anxiety, or in those currently experiencing arteriosclerosis, glaucoma, hyperthyroidism, or severe hypertension. However, a European consensus statement on adult ADHD noted that stimulants do\n\nA relatively sophisticated biochemical process is needed to produce dextroamphetamine from lisdexamfetamine. As opposed to Adderall, which contains amphetamine salts in a 3:1 dextro:levo ratio, lisdexamfetamine is a single-enantiomer dextroamphetamine formula. Studies conducted show that lisdexamfetamine dimesylate may have less abuse potential than dextroamphetamine and an abuse profile similar to diethylpropion at dosages that are FDA-approved for treatment of ADHD, but still has a high abuse potential when this dosage is exceeded by over 100%. The oral bioavailability of amphetamine varies with gastrointestinal pH; it is well absorbed from the gut, and bioavailability is typically 90%. Amphetamine is a weak base with a pKa of 9.9; consequently, when the pH is basic, more of the drug is in its lipid soluble free base form, and more is absorbed through the lipid-rich cell membranes of the gut epithelium.\n\nLisdexamfetamine dimesylate is one marketed formulation delivering dextroamphetamine. The following table compares the drug to other amphetamine pharmaceuticals. Lisdexamfetamine was developed by Robert Oberlender at New River Pharmaceuticals, under the name NRP104, before being bought by Takeda Pharmaceuticals through its acquisition of Shire Pharmaceuticals, prior to market release. It was developed to create a longer-lasting and less-easily abused version of dextroamphetamine, as the requirement of conversion into dextroamphetamine via enzymes in the red blood cells delays its onset of action, regardless of the route of administration. In February 2007, the US Food and Drug Administration (FDA) approved lisdexamfetamine for the treatment of ADHD. In August 2009, Health Canada approved the marketing of lisdexamfetamine for prescription use. In January 2015, lisdexamfetamine was approved by the FDA for the treatment of binge eating disorder in adults.\n\nThe Cochrane reviews on the treatment of ADHD in children, adolescents, and adults with pharmaceutical amphetamines stated that short-term studies have demonstrated that these drugs decrease the severity of symptoms, but they have higher discontinuation rates than non-stimulant medications due to their adverse side effects. However, a 2025 meta-analytic systematic review of 113 randomized controlled trials found that stimulant medications were the only intervention with robust short-term efficacy, and were associated with lower all-cause treatment discontinuation rates than non-stimulant medications (e.g., atomoxetine). A Cochrane review on the treatment of ADHD in children with tic disorders such as Tourette syndrome indicated that stimulants in general do not make tics worse, but high doses of dextroamphetamine could exacerbate tics in some individuals.\n\nLisdexamfetamine, sold under the brand names Vyvanse and Elvanse among others, is a stimulant medication that is used as a treatment for attention deficit hyperactivity disorder (ADHD) in children and adults and for moderate-to-severe binge eating disorder in adults. Lisdexamfetamine is taken by mouth. Its effects generally begin within 90 minutes and last for up to 14 hours. Common side effects of lisdexamfetamine include loss of appetite, anxiety, diarrhea, trouble sleeping, irritability, and nausea. Rare but serious side effects include mania, sudden cardiac death in those with underlying heart problems, and psychosis. It has a high potential for substance abuse. Serotonin syndrome may occur if used with certain other medications. Its use during pregnancy may result in harm to the baby and use during breastfeeding is not recommended by the manufacturer.",
                "is_citable": true,
                "prompt_context_metadata": {
                  "age": "3 days ago",
                  "url": "https://en.wikipedia.org/wiki/Lisdexamfetamine"
                }
              },
              {
                "type": "knowledge",
                "title": "Dextroamphetamine - Wikipedia",
                "url": "https://en.wikipedia.org/wiki/Dextroamphetamine",
                "metadata": {
                  "type": "webpage_metadata",
                  "site_domain": "wikipedia.org",
                  "favicon_url": "https://www.google.com/s2/favicons?sz=64&domain=wikipedia.org",
                  "site_name": "Wikipedia"
                },
                "is_missing": false,
                "text": "Dextroamphetamine (INN: dexamfetamine) is a potent central nervous system (CNS) stimulant and enantiomer of amphetamine that is used in the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. It is also used illicitly to enhance cognitive and athletic performance, and recreationally as an aphrodisiac and euphoriant. Dextroamphetamine is generally regarded as the prototypical stimulant. The amphetamine molecule exists as two enantiomers, levoamphetamine and dextroamphetamine. Dextroamphetamine is the dextrorotatory, or &#x27;right-handed&#x27;, enantiomer and exhibits more pronou\n\nThe conversion rate between dextroamphetamine sulfate to amphetamine free base is .728. In Australia, dexamfetamine is available in bottles of 100 instant release 5 mg tablets as a generic drug or slow release dextroamphetamine preparations may be compounded by individual chemists. In the United Kingdom, it is available in 5 mg instant release sulfate tablets under the generic name dexamfetamine sulfate as well as 10 mg and 20 mg strength tablets under the brand name Amfexa. It is also available in generic dexamfetamine sulfate 5 mg/ml oral sugar-free syrup. The brand name Dexedrine was available in the United Kingdom prior to UCB Pharma disinvesting the product to another pharmaceutical company (Auden Mckenzie). Dextroamphetamine is the active metabolite of the prodrug lisdexamfetamine (L-lysine-dextroamphetamine), available by the brand name Vyvanse (Elvanse in the European market) (Venvanse in the Brazil market) (lisdexamfetamine dimesylate).\n\nDextroamphetamine is liberated from lisdexamfetamine enzymatically following contact with red blood cells. The conversion is rate-limited by the enzyme, which prevents high blood concentrations of dextroamphetamine and reduces lisdexamfetamine's drug liking and abuse potential at clinical doses. Vyvanse is marketed as once-a-day dosing as it provides a slow release of dextroamphetamine into the body. Vyvanse is available as capsules, and chewable tablets, and in seven strengths; 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg. The conversion rate between lisdexamfetamine dimesylate (Vyvanse) to dextroamphetamine base is 29.5%. Another pharmaceutical that contains dextroamphetamine is commonly known by the brand name Adderall. It is available as immediate release (IR) tablets and extended release (XR) capsules. Adderall contains equal amounts of four amphetamine salts: One-quarter racemic (d,l-)amphetamine aspartate monohydrate ...\n\nDextroamphetamine, like other amphetamines, elicits its stimulating effects via several distinct actions: it inhibits or reverses the transporter proteins for the monoamine neurotransmitters (namely the serotonin, norepinephrine and dopamine transporters) either via trace amine-associated receptor 1 (TAAR1) or in a TAAR1 independent fashion when there are high cytosolic concentrations of the monoamine neurotransmitters and it releases these neurotransmitters from synaptic vesicles via vesicular monoamine transporter 2 (VMAT2). It also shares many chemical and pharmacological properties with human trace amines, particularly phenethylamine and N-methylphenethylamine, the latter being an isomer of amphetamine produced within the human body. It is available as a generic medication. In 2022, mixed amphetamine salts (Adderall) was the 14th most commonly prescribed medication in the United States, with more than 34 million prescriptions. Dextroamphetamine is used to treat attention deficit hy\n\nThe Cochrane reviews on the treatment of ADHD in children, adolescents, and adults with pharmaceutical amphetamines stated that short-term studies have demonstrated that these drugs decrease the severity of symptoms, but they have higher discontinuation rates than non-stimulant medications due to their adverse side effects. However, a 2025 meta-analytic systematic review of 113 randomized controlled trials found that stimulant medications were the only intervention with robust short-term efficacy, and were associated with lower all-cause treatment discontinuation rates than non-stimulant medications (e.g., atomoxetine). A Cochrane review on the treatment of ADHD in children with tic disorders such as Tourette syndrome indicated that stimulants in general do not make tics worse, but high doses of dextroamphetamine could exacerbate tics in some individuals.",
                "is_citable": true,
                "prompt_context_metadata": {
                  "age": "1 week ago",
                  "url": "https://en.wikipedia.org/wiki/Dextroamphetamine"
                }
              },
              {
                "type": "knowledge",
                "title": "Dexamphetamine - Alcohol and Drug Foundation",
                "url": "https://adf.org.au/drug-facts/dexamphetamine/",
                "metadata": {
                  "type": "webpage_metadata",
                  "site_domain": "adf.org.au",
                  "favicon_url": "https://www.google.com/s2/favicons?sz=64&domain=adf.org.au",
                  "site_name": "Adf"
                },
                "is_missing": false,
                "text": "Understand how dexamphetamine treats ADHD and narcolepsy by altering brain chemistry. Learn about proper usage, potential side effects, and risks of non-prescribed use.\n\nDexamphetamine is a medication prescribed to treat attention deficit hyperactivity disorder (ADHD) and narcolepsy (a sleep disorder).1 Dexamphetamine is a Schedule 8 drug in Australia which means it is tightly controlled and requires a prescription.3 · Dexamphetamine is also sometimes used by people without a prescription to increase alertness or to get ‘high’.4 · Dexamphetamine is usually a small, round, white tablet. It can also be a capsule and can come in short acting or long acting forms.6 · Dexamphetamine Sulfate (Sigma), Dextroamphetamine, Dexamfetamine, lisdexamfetamine, Vyvanse, dexies, dex. ... Dexamphetamine is usually swallowed or crushed and snorted, but is sometimes injected or smoked/inhaled.7 · Use of any drug can have risks. It’s important to be careful when taking any type of drug. Prescribed stimulants work on the parts of the brain involved in regulating attention and arousal (being alert and awake).\n\nUebel-von Sandersleben H, Dangel O, Fischer R, Ruhmann M, Huss M. Effectiveness and safety of dexamphetamine sulfate (Attentin) in the routine treatment of children and adolescents with ADHD: results from a 12-month non-interventional study. Scandinavian Journal of Child and Adolescent Psychiatry and Psychology [Internet]. 2021 [10.05.2024]; 9(1):[73-86 pp.]. Shoar N Marwaha R Molla M. Dextroamphetamine-Amphetamine 2022 [15.02.2023]. Lohr D Wanta J Baker M Grudnikoff E Morgan W Chhabra D Lee T. Intentional Discontinuation of Psychostimulants Used to Treat ADHD in Youth: A Review and Analysis. Frontiers in Psychiatry [Internet]. 2021 [05.06.2024]; 12. Smith G Jongeling B Hartmann P Russell C Landau L. Long-term outcomes associated with stimulant medication in the treatment of ADHD in children 2010 [05.06.2024]. Healthline. Vyvanse Crash: What It Is and How to Deal with It 2017 [14.05.2024]. Healthline.\n\nNSW Health. ADHD - frequently asked questions 2023 [16.05.2024]. Kaye S, Darke S. The diversion and misuse of pharmaceutical stimulants: what do we know and why should we care? Addiction [Internet]. 2012 [16.05.2024]; 107(3):[467-77 pp.]. Huang C-L, Tsai IJ, Lee CW-S. Risk of psychosis in illicit amphetamine users: a 10 year retrospective cohort study. Evidence Based Mental Health [Internet]. 2022 [16.05.2024]; 25(4):[163 p.]. Handelman K, Sumiya F. Tolerance to Stimulant Medication for Attention Deficit Hyperactivity Disorder: Literature Review and Case Report. Brain Sci [Internet]. 2022 [21.05.2024]; 12(8). Psychonaut Wiki. dextroamphetamine 2023 [21.05.2024]. Zealand MN. New Zealand Data Sheet: Aspen Dexamfetamine 2022 [21.05.2024]. 24. Tucker JA, Darke, S, Lappin, J, Farrell, M. The Clinicians Guide to Illicit Drugs and Health: Silverback Publishing; 2019 [17.01.2024]. 25.\n\nDexamphetamine and alcohol: may feel less intoxicated due to stimulant effects of amphetamine and lead to drinking more. Increases risk of alcohol poisoning. Dexamphetamine and tricyclic antidepressants/MAOI inhibitors: increased heart rate and blood pressure.22,23 · Polydrug use is a term for the use of more than one drug or type of drug at the same time or one after another. Polydrug use can involve both illicit drugs and legal substances, such as alcohol and medications. ... Only take as prescribed and don’t change dose without first speaking with your prescribing doctor/specialist · Check with your doctor before taking any other medications or supplements · Until you know how dexamphetamine affects you, be careful when driving, operating machinery or doing heavy exercise · Avoid mixing dexamphetamine with alcohol or other drugs Reducing the risk of harm from non-prescribed use: Use where you feel safe and with people you trust, and always tell someone what you’ve taken ...",
                "is_citable": true,
                "prompt_context_metadata": {
                  "url": "https://adf.org.au/drug-facts/dexamphetamine/"
                }
              },
              {
                "type": "knowledge",
                "title": "Dextroamphetamine and Amphetamine: MedlinePlus Drug Information",
                "url": "https://medlineplus.gov/druginfo/meds/a601234.html",
                "metadata": {
                  "type": "webpage_metadata",
                  "site_domain": "medlineplus.gov",
                  "favicon_url": "https://www.google.com/s2/favicons?sz=64&domain=medlineplus.gov",
                  "site_name": "MedlinePlus"
                },
                "is_missing": false,
                "text": "Dextroamphetamine and Amphetamine: learn about side effects, dosage, special precautions, and more on MedlinePlus\n\nThe combination of dextroamphetamine and amphetamine (Adderall, Adderall XR, Mydayis) is used as part of a treatment program to control symptoms of attention deficit hyperactivity disorder (ADHD; more difficulty focusing, controlling actions, and remaining still or quiet than other people who are the same age). Adderall is used to treat ADHD in adults and children 3 years of age and older. Adderall XR is used to treat ADHD in adults and children 6 years of age and older. Mydayis is used to treat ADHD in adults and children 13 years of age and older. Dextroamphetamine and amphetamine (Adderall) is also used to treat narcolepsy (a sleep disorder that causes excessive daytime sleepiness and sudden attacks of sleep) in adults and children 12 years of age and older. The combination of dextroamphetamine and amphetamine is in a class of medications called central nervous system stimulants.\n\ntell your doctor and pharmacist if you are allergic to amphetamine, dextroamphetamine, other stimulant medications such as benzphetamine, lisdexamfetamine (Vyvanse), or methamphetamine (Desoxyn); any other medications, or any of the ingredients in dextroamphetamine and amphetamine preparations. Ask your pharmacist for a list of the ingredients. tell your doctor or pharmacist if you are taking the following medications or have stopped taking them within the past two weeks: monoamine oxidase (MAO) inhibitors including isocarboxazid (Marplan), linezolid (Zyvox), methylene blue, phenelzine (Nardil), selegiline (Eldepryl, Emsam, Zelapar), or tranylcypromine (Parnate). some medications should not be taken with dextroamphetamine and amphetamine. Other medications may cause dosing changes or extra monitoring when taken with dextroamphetamine and amphetamine.\n\nyou should know that dextroamphetamine and amphetamine should be used as part of a total treatment program for ADHD, which may include counseling and special education. Make sure to follow all of your doctor's and/or therapist's instructions. you should know that dextroamphetamine and amphetamine may cause sudden death in children and teenagers, especially children and teenagers who have heart defects or serious heart problems. This medication also may cause sudden death, heart attack, or stroke in adults, especially adults with heart defects or serious heart problems. Call your or your child's doctor right away and get emergency help, if you or your child has any signs of heart problems while taking this medication including: chest pain, shortness of breath, or fainting. Unless your doctor tells you otherwise, continue your normal diet. If you miss your dose of the extended-release capsule the morning, skip the missed dose and take your next dose at the regular time the next day.\n\nYou or your caregiver should tell your doctor immediately, if you experience any of the following symptoms: fast, pounding, or irregular heartbeat; sweating; dilated pupils; abnormally excited mood; restlessness; irritability; difficulty falling sleeping or staying asleep; hostility; aggression; anxiety; loss of appetite; loss of coordination; uncontrollable movement of a part of the body; flushed skin; vomiting; stomach pain; or thinking about harming or killing oneself or others or planning or trying to do so. Overusing dextroamphetamine and amphetamine may also cause serious heart problems or sudden death. Tell your doctor if you or anyone in your family drinks or has ever drunk large amounts of alcohol, uses or has ever used street drugs, or has overused prescription medications. Your doctor will probably not prescribe dextroamphetamine and amphetamine for you.",
                "is_citable": true,
                "prompt_context_metadata": {
                  "url": "https://medlineplus.gov/druginfo/meds/a601234.html"
                }
              },
              {
                "type": "knowledge",
                "title": "ADHD medication list: A comparison guide",
                "url": "https://www.medicalnewstoday.com/articles/325201",
                "metadata": {
                  "type": "webpage_metadata",
                  "site_domain": "medicalnewstoday.com",
                  "favicon_url": "https://www.google.com/s2/favicons?sz=64&domain=medicalnewstoday.com",
                  "site_name": "Medicalnewstoday"
                },
                "is_missing": false,
                "text": "Doctors can prescribe this medication to children, adolescents, and adults with ADHD. As a long-acting medication, it provides symptom control for 10–12 hours. Sometimes, doctors will need to prescribe a short-acting amphetamine drug to provide symptom control later in the afternoon. Vyvanse contains lisdexamfetamine, an inactive form of amphetamine. When a person takes Vyvanse, their body converts the inactive medication into dextroamphetamine. Vyvanse has similar effects to Adderall XR. Children can manage their ADHD symptoms for 13 hours when taking Vyvanse. Adults who take Vyvanse can achi\n\nThere are many different ADHD medications. This article lists ADHD medications and discusses the side effects, risks, and benefits of different types.\n\nXelstrym is an amphetamine patch approved by the FDA in 2022 for the treatment of ADHD. It contains dextroamphetamine, the same active ingredient in Dexedrine and Dexedrine Spansules. The patch is applied daily and should be worn for a maximum of 9 hours. A person should use one patch per day. Mydayis is a newer formulation of dextroamphetamine and amphetamine. It is a capsule typically taken once a day when a person first wakes up. This medication is designed to be longer-acting than other amphetamine formulations. One capsule may work for up to ... These medications are long-acting forms of amphetamine approved for use in people over the age of 6 years. A person typically takes them once a day, in the morning. Adzenys XR-ODT is a quick-dissolve tablet that people can take without water. Adzenys ER and Dyanavel XR are liquid formulations. Quillivant XR and QuilliChew ER contain methylphenidate in two forms.\n\nProcentra and Zenzedi are medications containing dextroamphetamine. Procentra is a liquid, while Zenzedi is the brand name for a newer tablet form. Doctors can prescribe Zenzedi for children as young as · 3 years old. Children ages 3–5 years typically take this medication once per day, while children 6 years and older may take it once or twice daily. Nonstimulant medications act on a set of different pathways that offer another treatment option. Doctors may prescribe nonstimulant medications in combination with stimulants or alone. Some people cannot tolerate the side effects of stimulant medications and can only take nonstimulants. When people use nonstimulant medications, they may only notice that their symptoms start to improve after about 4–8 weeks. As a result, this treatment is not appropriate for people who require urgent symptom management. There are several nonstimulant drugs available for ADHD: ...\n\nStimulants act on norepinephrine and dopamine, two brain chemicals that may play a role in ADHD. Stimulants called amphetamines are more effective and produce fewer side effects in adults. The first choice for children and adolescents with ADHD is methylphenidate. The most common side effects of stimulant medications for ADHD are: ... Serious heart-related complications are rare. Doctors should closely monitor people with heart problems who are taking stimulants. Central nervous system stimulants have a high potential for misuse and dependence. Longer-acting formulations have a lower potential for misuse, so doctors more commonly prescribe these. Stimulants can interact with several medications. Some people have both ADHD and depression or anxiety. For this reason, doctors may prescribe an antidepressant or antianxiety medication with a stimulant for ADHD treatment.",
                "is_citable": true,
                "prompt_context_metadata": {
                  "age": "January 25, 2024",
                  "url": "https://www.medicalnewstoday.com/articles/325201"
                }
              },
              {
                "type": "knowledge",
                "title": "Adderall vs. Vyvanse: What's the Difference?",
                "url": "https://americanaddictioncenters.org/stimulants/amphetamine/adderall/vs-vyvanse",
                "metadata": {
                  "type": "webpage_metadata",
                  "site_domain": "americanaddictioncenters.org",
                  "favicon_url": "https://www.google.com/s2/favicons?sz=64&domain=americanaddictioncenters.org",
                  "site_name": "Americanaddictioncenters"
                },
                "is_missing": false,
                "text": "Adderall (amphetamine and dextroamphetamine) and Vyvanse (lisdexamfetamine) are central nervous system stimulant medications. They are both approved to treat ADHD (attention deficit hyperactivity disorder). Vyvanse is not approved for use for children under the age of 6. Adderall is also approved to treat the sleep disorder narcolepsy, and Vyvanse is approved by the Food and Drug Administration to treat binge eating disorder in individuals over the age of 18. Both drugs are classified as controlled substances by the United States Drug Enforcement Administration in the Schedule II category, indicating that they are at the highest level of control for drugs that can be obtained by people with a prescription from a physician. This means that the federal government considers both of these drugs to have a significant potential to produce physical dependence in people who use them and are high-risk potential drugs of misuse.\n\nAdderall and Vyvanse are both stimulants; however, they differ in several ways. Learn the similarities and differences between these drugs.\n\nThe approved uses for Adderall include the treatment of ADHD and narcolepsy; the approved uses for Vyvanse include to treat ADHD and binge eating disorder. The active ingredients in Adderall are dextroamphetamine (about 75% of the drug) and levoamphetamine (about 25% of the drug); the active ingredient in Vyvanse is lisdexamfetamine. Adderall comes in an immediate-release form and an extended-release form; Vyvanse comes in a capsule form that is an extended-release version. The duration of action for the immediate-release version of Adderall is about 4–6 hours, whereas the extended-release version lasts about 12 hours. The duration of effects for Vyvanse is about 10–13 hours, though some studies report it is up to 14 hours. Both drugs have a very similar side effect profile. However, Vyvanse is a prodrug, which is an inert substance that is metabolized in the body to become an active medication.\n\nThe lisdexamfetamine in Vyvanse is metabolized into dextroamphetamine and then functions by increasing the availability of dopamine and norepinephrine in the central nervous system. The half-life of Adderall is about 11–13 hours; the half-life of the Vyvanse is about 10–12 hours. Adderall can be obtained in a generic version that can be relatively inexpensive; there is currently no generic Vyvanse available. The biggest differences between the two drugs are how they are metabolized by the body, how often a person needs to take them (especially in the case of the immediate-release version of Adderall versus Vyvanse), and their projected potential to be drugs of misuse. The decision whether to prescribed Adderall or Vyvanse is made by a physician based on the physician’s knowledge of the patient, the side effect profile of the drug, and the specific symptoms the physician is attempting to address.",
                "is_citable": true,
                "prompt_context_metadata": {
                  "age": "November 21, 2024",
                  "url": "https://americanaddictioncenters.org/stimulants/amphetamine/adderall/vs-vyvanse"
                }
              },
              {
                "type": "knowledge",
                "title": "Vyvanse or Adderall: Which ADHD Treatment Is Right for You?",
                "url": "https://www.webmd.com/add-adhd/vyvanse-adderall-difference",
                "metadata": {
                  "type": "webpage_metadata",
                  "site_domain": "webmd.com",
                  "favicon_url": "https://www.google.com/s2/favicons?sz=64&domain=webmd.com",
                  "site_name": "WebMD"
                },
                "is_missing": false,
                "text": "Children and adults with ADHD can choose among many drug treatment options, including Vyvanse and Adderall. (Photo Credit: Science Photo Library/Getty Images) Adderall is the brand name for a mix of two stimulants called amphetamine-dextroamphetamine. It comes in a capsule full of beads that hold these medicines, which are also called mixed amphetamine salts. A capsule of Adderall can contain between 5 and 30 milligrams of the medicine. A dose of the original form lasts about 4 hours in your body. The longer-acting form, called Adderall XR, comes in the same sizes but can last 8-12 hours. This is because half the beads are fast-acting, and the others are slow-acting. Vyvanse is the brand name for lisdexamfetamine dimesylate. It comes in capsules, with 10-70 milligrams of medicine, and chewable tablets, with 10-60 milligrams of medicine. It also has the stimulant amphetamine but adds a compound called lysine.\n\nVyvanse Vs. Adderall: Learn the similarities and differences between Vyvanse and Adderall, both popular stimulants used to treat ADHD\n\nStudies comparing the drugs are limited. One analysis of 20 studies found that in adults, ADHD symptoms improved significantly with either lisdexamfetamine (Vyvanse) or mixed amphetamine salts (Adderall), but the effects were somewhat stronger with Vyvanse. It's best to talk with your doctor about the best medication choice for you or your child. For example, school-age children often need shorter-acting medicines so that they can get enough sleep and Vyvanse doesn't come in a short-acting form. Another thing to consider if you are choosing between Vyvanse and Adderall, or other alternatives, is the way they might interact with other medicines you or your child take. You can find warnings about potential interactions on the patient information insert that comes with the drug. Because Adderall, Adderall XR, and Vyvanse are all amphetamines, they interact with many other medicines in similar ways.\n\nVyvanse and Adderall are drugs used by many children and adults to treat attention deficit hyperactivity disorder (ADHD). Both are stimulants called amphetamines. They work by raising levels of chemicals in your brain called dopamine and norepinephrine that help you focus, control your impulses, and pay attention at school or work. About 80% of people notice that their symptoms are better when they take stimulants. Vyvanse and Adderall aren't exactly the same, though. They do different things in your body and can cause different side effects. You'll work with your doctor to find an ADHD treatment that's best for you. It might take some time to find the right medicine and dose. If the first one your doctor prescribes doesn't work, you can try a different one. ... In addition to Vyvanse, Adderall, and their generic versions, other stimulant drugs on the market include forms of methylphenidate, such as Ritalin and Concerta, which are not amphetamines but work in similar ways.",
                "is_citable": true,
                "prompt_context_metadata": {
                  "age": "June 30, 2024",
                  "url": "https://www.webmd.com/add-adhd/vyvanse-adderall-difference"
                }
              },
              {
                "type": "knowledge",
                "title": "Lisdexamfetamine Dimesylate and Methylphenidate and Dextroamphetamine in Attention Deficit Disorder With Hyperactivity - Clinical Trials Registry - ICH GCP",
                "url": "https://ichgcp.net/clinical-trials-registry/NCT04132557",
                "metadata": {
                  "type": "webpage_metadata",
                  "site_domain": "ichgcp.net",
                  "favicon_url": "https://www.google.com/s2/favicons?sz=64&domain=ichgcp.net",
                  "site_name": "Ichgcp"
                },
                "is_missing": false,
                "text": "The purpose of this study is to estimate the observed incidence of the health outcomes (suicide attempt or ideation, suicide ideation, suicide attempt, psychosis, and substance abuse) in a cohort of participants diagnosed with attention deficit hyperactivity disorder (ADHD) who are first-line new therapy with methylphenidate monotherapy, lisdexamfetamine monotherapy, atomoxetine monotherapy, amphetamine/dextroamphetamine combo therapy, and either methylphenidate/lisdexamfetamine/atomoxetine monotherapy or amphetamine/dextroamphetamine combo therapy during the &#x27;on treatment&#x27; period from 7 days \n\nThe purpose of this study is to estimate the observed incidence of the health outcomes (suicide attempt or ideation, suicide ideation, suicide attempt, psychosis, and substance abuse) in a cohort of participants diagnosed with attention deficit hyperactivity disorder (ADHD) who are first-line new therapy with methylphenidate monotherapy, lisdexamfetamine monotherapy, atomoxetine monotherapy, amphetamine/dextroamphetamine combo therapy, and either methylphenidate/lisdexamfetamine/atomoxetine monotherapy or amphetamine/dextroamphetamine combo therapy during the 'on treatment' period from 7 days after the start of exposure through the end of exposure (treatment discontinuation for at least 60 days) and the 'intent to treat' period from 7 days after start of treatment to end of continuous observation; and to compare the hazards of outcomes (suicide attempt or ideation, suicide ideation, suicide attempt, psychosis, and substance abuse) in the target cohort (participants diagnosed with ADHD \n\nThe study population will comprise of participants with attention deficit/hyperactivity disorder (ADHD) described in on three US health care databases and one US electronic health record which has data available through 1 January 2001 to 30 September 2018. ... New users of methylphenidate monotherapy or lisdexamfetamine monotherapy or atomoxetine monotherapy or amphetamine/dextroamphetamine combo therapy ... This section provides details of the study plan, including how the study is designed and what the study is measuring. ... This is where you will find people and organizations involved with this study. ... These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.\n\nPhase 3 Efficacy and Safety Laboratory Classroom Study in Pediatrics (6-12) With ADHD Using CTx-1301 · ADHD | Attention Deficit Hyperactivity Disorder | Attention Deficit Disorder With Hyperactivity | ADHD - Combined Type | Attention Deficit Hyperactivity Disorder Combined | Attention Deficit Hyper Activity | Attention-deficit Hyperactivity ... Capital Medical University; Peking Union Medical College; Chinese Academy of... ... An Intervention Study on Transcranial Photobiomodulation in Children with Attention Deficit Hyperactivity Disorder · ADHD - Attention Deficit Disorder with Hyperactivity ... Effect of Nutritional Formula Supplementation on Growth of Prepubertal Children Treated With Stimulants Medications for Attention Deficit Hyperactivity Disorder (ADHD) ADHD - Attention Deficit Disorder With Hyperactivity ... The Study of Efficacy and Safety of Generic Methylphenidate Prolong-released Comparison With Original ...\n\nBehavioral Treatment, Drug Treatment, and Combined Treatment for Attention Deficit Hyperactivity Disorder (ADHD) ... Methylphenidate for Treating Attention Deficit Hyperactivity Disorder in Children With Both ADHD and Epilepsy · Epilepsy | Attention Deficit Disorder With Hyperactivity ... McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. ... Study Examining Repeat Dosing of OROS® Methylphenidate (CONCERTA®) and Immediate Release Methylphenidate in Healthy Adults ... McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. ... A PET Study Examining Pharmacokinetics and Dopamine Transporter Receptor Occupancy Of Two Long-Acting Formulations of Methylphenidate in Adults ... Milton S. Hershey Medical Center ... McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. ... Naturalistic Substitution of Concerta in Adult Subject With ADHD Receiving Immediate Release Methylphenidate ...",
                "is_citable": true,
                "prompt_context_metadata": {
                  "age": "November 7, 2019",
                  "url": "https://ichgcp.net/clinical-trials-registry/NCT04132557"
                }
              },
              {
                "type": "knowledge",
                "title": "Amphetamine - Wikipedia",
                "url": "https://en.wikipedia.org/wiki/Amphetamine",
                "metadata": {
                  "type": "webpage_metadata",
                  "site_domain": "wikipedia.org",
                  "favicon_url": "https://www.google.com/s2/favicons?sz=64&domain=wikipedia.org",
                  "site_name": "Wikipedia"
                },
                "is_missing": false,
                "text": "However, a 2025 meta-analytic ... discontinuation rates than non-stimulant medications (e.g., atomoxetine). A Cochrane review on the treatment of ADHD in children with tic disorders such as Tourette syndrome indicated that stimulants in general do not make tics worse, but high doses of dextroamphetamine could exacerbate tics in some individuals. Binge eating disorder (BED) is characterized by recurrent and persistent episodes of compulsive binge eating. These episodes are often accompanied by marked distress and a feeling of loss of control over eating. The pathophysiology of BED is not fully \n\nHowever, a 2025 meta-analytic systematic review of 113 randomized controlled trials found that stimulant medications were the only intervention with robust short-term efficacy, and were associated with lower all-cause treatment discontinuation rates than non-stimulant medications (e.g., atomoxetine). A Cochrane review on the treatment of ADHD in children with tic disorders such as Tourette syndrome indicated that stimulants in general do not make tics worse, but high doses of dextroamphetamine could exacerbate tics in some individuals. Binge eating disorder (BED) is characterized by recurrent and persistent episodes of compulsive binge eating. These episodes are often accompanied by marked distress and a feeling of loss of control over eating. The pathophysiology of BED is not fully understood, but it is believed to involve dysfunctional dopaminergic reward circuitry along the cortico-striatal-thalamic-cortical loop. As of July 2024, lisdexamfetamine is the only USFDA- and TGA-approved\n\nEvidence suggests that lisdexamfetamine's treatment efficacy in BED is underpinned at least in part by a psychopathological overlap between BED and ADHD, with the latter conceptualized as a cognitive control disorder that also benefits from treatment with lisdexamfetamine. Lisdexamfetamine's therapeutic effects for BED primarily involve direct action in the central nervous system after conversion to its pharmacologically active metabolite, dextroamphetamine. Centrally, dextroamphetamine increases neurotransmitter activity of dopamine and norepinephrine in prefrontal cortical regions that regulate cognitive control of behavior. Similar to its therapeutic effect in ADHD, dextroamphetamine enhances cognitive control and may reduce impulsivity in patients with BED by enhancing the cognitive processes responsible for overriding prepotent feeding responses that precede binge eating episodes.\n\namine) is a central nervous system (CNS) stimulant that is used in the treatment of attention deficit hyperactivity disorder (ADHD), narcolepsy, and obesity; it is also used to treat binge eating disorder in the form of its inactive prodrug lisdexamfetamine. Amphetamine was discovered as a chemical in 1887 by Lazăr Edeleanu, and then as a drug in the late 1920s. It exists as two enantiomers: levoamphetamine and dextroamphetamine. Amphetamine properly refers to a specific chemical, the racemic free base, which is equal parts of the two enantiomers in their pure amine forms. The term is frequently used informally to refer to any combination of the enantiomers, or to either of them alone. Historically, it has been used to treat nasal congestion and depression. Amphetamine is also used as an athletic performance enhancer and cognitive enhancer, and recreationally as an aphrodisiac and euphoriant.\n\nThe first amphetamine pharmaceutical was Benzedrine, a brand which was used to treat a variety of conditions. Pharmaceutical amphetamine is prescribed as racemic amphetamine, Adderall, dextroamphetamine, or the inactive prodrug lisdexamfetamine. Amphetamine increases monoamine and excitatory neurotransmission in the brain, with its most pronounced effects targeting the norepinephrine and dopamine neurotransmitter systems. At therapeutic doses, amphetamine causes emotional and cognitive effects such as euphoria, change in desire for sex, increased wakefulness, and improved cognitive control. It induces physical effects such as improved reaction time, fatigue resistance, decreased appetite, elevated heart rate, and increased muscle strength. Larger doses of amphetamine may impair cognitive function and induce rapid muscle breakdown. Addiction is a serious risk with heavy recreational amphetamine use, but is unlikely to occur from long-term medical use at therapeutic doses.\n\nHighly acidic urine will reduce the enantiomer half-lives to 7 hours; highly alkaline urine will increase the half-lives up to 34 hours. The immediate-release and extended release variants of salts of both isomers reach peak plasma concentrations at 3 hours and 7 hours post-dose respectively. Amphetamine is eliminated via the kidneys, with 30–40% of the drug being excreted unchanged at normal urinary pH. When the urinary pH is basic, amphetamine is in its free base form, so less is excreted. When urine pH is abnormal, the urinary recovery of amphetamine may range from a low of 1% to a high of 75%, depending mostly upon whether urine is too basic or acidic, respectively. Following oral administration, amphetamine appears in urine within 3 hours. Roughly 90% of ingested amphetamine is eliminated 3 days after the last oral dose.  · Lisdexamfetamine is a prodrug of dextroamphetamine.",
                "is_citable": true,
                "prompt_context_metadata": {
                  "age": "1 day ago",
                  "url": "https://en.wikipedia.org/wiki/Amphetamine"
                }
              },
              {
                "type": "text",
                "text": "<system>You only have 18 searches left this turn</system>\n\n",
                "uuid": "f24e332f-7611-4da3-b49c-8e1e83bebbfe"
              }
            ],
            "is_error": false,
            "message": null,
            "integration_name": null,
            "integration_icon_url": null,
            "display_content": null
          },
          {
            "start_timestamp": "2025-05-28T11:05:16.051590Z",
            "stop_timestamp": "2025-05-28T11:05:16.491184Z",
            "flags": null,
            "type": "text",
            "text": "\n\nLet me search for more specific information about Belgium's available ADHD medications and their regulatory status.",
            "citations": []
          },
          {
            "start_timestamp": "2025-05-28T11:05:16.933675Z",
            "stop_timestamp": "2025-05-28T11:05:17.384053Z",
            "flags": null,
            "type": "tool_use",
            "name": "web_search",
            "input": {
              "query": "Belgium FAMHP approved ADHD medications list stimulants 2025"
            },
            "message": "Searching the web",
            "integration_name": null,
            "integration_icon_url": null,
            "context": null,
            "display_content": null,
            "approval_options": null,
            "approval_key": null
          },
          {
            "start_timestamp": null,
            "stop_timestamp": null,
            "flags": null,
            "type": "tool_result",
            "name": "web_search",
            "content": [
              {
                "type": "knowledge",
                "title": "Information for travellers | FAMHP",
                "url": "https://www.famhp.be/en/human_use/particular_products/specially_reglemented_substances/narcotics_psychotropics/informations_pour_les_voyageurs",
                "metadata": {
                  "type": "webpage_metadata",
                  "site_domain": "famhp.be",
                  "favicon_url": "https://www.google.com/s2/favicons?sz=64&domain=famhp.be",
                  "site_name": "Famhp"
                },
                "is_missing": false,
                "text": "If you are travelling and your medicine contains a substance referred to in the Royal Decree of 06/09/2017 regulating narcotic and psychotropic substances, you will need an official accompanying document proving that you were prescribed these medicines as part of a medical treatment.\n\nMedicines for the treatment of ADHD (e.g. medicines containing the active substance methylphenidate); Medicines used in substitution therapy (e.g. methadone, buprenorphine). ... The Schengen area consists of 27 countries: Austria, Belgium, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Italy, Latvia, Liechtenstein, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Slovakia, Slovenia, Spain, Sweden and Switzerland. More information · If you travel to one of these countries and take a medicine containing narcotic or psychotropic substances, you must send this form (in Dutch or in French) at least twenty working days (four weeks) in advance to: Federal Agency for Medicines and Health Products DG Inspection - Authorisations Division - Narcotics Team Avenue Galilée 5/03 1210 Brussels ·\n\nIt is forbidden to have narcotic or psychotropic substances sent to you from Belgium. After validation of the fully and correctly completed form, the document will be sent by post to the person concerned. Take the approved declaration with you when you travel and keep it with your medicines. Show the declaration when asked. The FAMHP is only competent for validating Schengen declarations of medicines containing narcotic or psychotropic substances for citizens domiciled in Belgium who must take these medicines with them during their journey to a country within the Schengen area. We do not validate documents for other medicines, citizens domiciled abroad or travels to countries outside the Schengen area. Travellers to Spain must also obtain a \"Permiso de Viajeros\" according to Spain's national legislation. The application can be submitted through the Spanish embassy in Belgium.\n\nMedicinal cannabis (dry buds) containing tetrahydrocannabinol: dispensing this type of product in Belgium is prohibited by the Royal Decree of 11 June 2015 regulating products containing one or more tetrahydrocannabinols. As a public service, we cannot validate a Schengen declaration for a product whose dispensing is prohibited in Belgium. If you use medicines as part of a substitution therapy (e.g. methadone, buprenorphine), always check the information of the country you are travelling to on the INCB website or contact the embassy of your travel destination. Such medicines are often subject to stricter rules or special procedures. Travelling outside the Schengen area No agreements have been concluded with countries outside the Schengen area on the bringing along of medicines containing narcotic or psychotropic substances. Before departure, consult the INCB website where you can find information on bringing along medicines to your destination according to the regulations.\n\nTravelling to Belgium A traveller who needs to bring along narcotic or psychotropic substances into Belgium as part of a medical treatment must be able to justify this by means of a valid medical prescription or a certificate validated by public authorities, such as the Schengen declaration. The maximum amount of medicines brought along to Belgium may not exceed a treatment duration of 3 months. If your travel lasts longer than 30 days and this is the limit of the country of origin or your travel takes longer than 3 months, you should contact a doctor in Belgium. In this way, your medical treatment can be followed up correctly. It is forbidden to have narcotic or psychotropic substances sent to Belgium.",
                "is_citable": true,
                "prompt_context_metadata": {
                  "url": "https://www.famhp.be/en/human_use/particular_products/specially_reglemented_substances/narcotics_psychotropics/informations_pour_les_voyageurs"
                }
              },
              {
                "type": "knowledge",
                "title": "1 in 20 university students uses stimulant medicines in order to study better | FAMHP",
                "url": "https://www.famhp.be/en/news/1_in_20_university_students_uses_stimulant_medicines_in_order_to_study_better",
                "metadata": {
                  "type": "webpage_metadata",
                  "site_domain": "famhp.be",
                  "favicon_url": "https://www.google.com/s2/favicons?sz=64&domain=famhp.be",
                  "site_name": "Famhp"
                },
                "is_missing": false,
                "text": "The FAMHP asked more than 12,000 francophone university students about the use of stimulant drugs. 5% of them said to use stimulant medicines for non-medical use, in order to study better.\n\nStimulant medicines containing methylphenidate, modafinil, pitolisant and atmoxetine (list of medicines that are commercialised in Belgium) are approved for the treatment of attention deficit and disorder with or without hyperactivity (ADD/ADHD) and narcolepsy. These are prescription medicines. Abuse can lead to healthproblems such as heart problems, elevated blood pressure, insomnia, depression, panic attacks and addiction. ... Some students use stimulants in the hope of improving their study performance. In Flanders, regular surveys are being performed in order to investigate drug use and the use of stimulant medicines in students. For francophone universities in Belgium there were no data. Therefore, the Department of Vigilance of the FAMHP performed a survey for these students. The survey was performed in October and November 2018 at six francophone universities in Belgium.\n\nFurther information Reporting abuse or misuse of medicines (Dutch or French only) Educational material on methylphenidate (Dutch only) Studies and medication in Flanders campaign (Dutch only) ADHD Health Care Path (Dutch or French only) FAMHP campaigns Een geneesmiddel is geen snoepje. Geneesmiddelen via internet? Surf niet met uw gezondheid! Commercialised stimulant medicines in Belgium Concerta®, Equasym®, Medikinet®, Methylfenidaat Sandoz®, Methylphenidate Mylan®, Rilatine®, Provigil®, Xyrem® en Wakix®\n\nStimulant medicines without medical prescription are used to improve study performance. Better concentration while studying, being able to study longer and improving study performance were by far the most significant reasons why these medicines are used. Using them as a party drug or for weight loss, however, is rather rare. The use of stimulant medicines is more frequent during the revision and exam period. While most medical users take these medicines at least on a weekly basis, non-medical users take them more sporadically. Users notice side effects. In both medical and non-medical users of stimulant drugs, the most frequently reported negative effects were sleep disorders, heart palpitations and emotional instability. In general, stimulant medicines are commonly associated with headache, nervousness, agitation, decrease in appetite, nausea and stomach ache.\n\nStimulant medicines for non-medical use are mostly acquired via friends and acquaintances. Friends or acquaintances within and outside of the student community are the most significant source of stimulant medicines for non-medical use. This suggests some patients in medical treatment are sharing their medicines with their friends. 8% of non-medical users acquired these medicines via illegal online channels. Numbers are in line with those of other studies. A European overview study from 2015 shows 1% to 16% of students taking stimulant medicines for non-medical use. Flemish university and college students report a non-medical use of 9% in 2017. The design and execution of these studies, however, were different. Therefore, results of the new survey cannot be directly compared to those of these previous studies. From research by the socialist mutualities in 2018 it appeared that Flemish youngsters use more stimulant medicines than their counterparts in Wallonia or Brussels.",
                "is_citable": true,
                "prompt_context_metadata": {
                  "url": "https://www.famhp.be/en/news/1_in_20_university_students_uses_stimulant_medicines_in_order_to_study_better"
                }
              },
              {
                "type": "knowledge",
                "title": "Belgium Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Report 2022 to 2030",
                "url": "https://www.insights10.com/report/belgium-adhd-attention-deficit-hyperactivity-disorder-therapeutic-market-analysis/",
                "metadata": {
                  "type": "webpage_metadata",
                  "site_domain": "insights10.com",
                  "favicon_url": "https://www.google.com/s2/favicons?sz=64&domain=insights10.com",
                  "site_name": "Insights10"
                },
                "is_missing": false,
                "text": "Belgium&#x27;s attention deficit hyperactivity disorder therapeutics market is expected to witness growth from $65 Mn in 2022 to $116 Mn in 2030 with a CAGR of 7.5% for the year 2022-30.\n\nFinancial hardships or resource limitations may make it more challenging for patients to receive treatment for ADHD. This may restrict the Belgium ADHD therapeutics market expansion. Some patients may experience negative side effects from their ADHD therapies, which may cause them to discontinue taking it or reduce their desire to take it. This might slow the Belgium ADHD therapeutics market's expansion. ... The Federal Agency for Medicines and Health Products, formerly the Directorate-General for Medicinal Products of the FPS Public Health (Agence Federerale des Medicaments et des Produits de Sante, FAMHP), was established in January 2007 and serves as Belgium's official agency for licensing pharmaceuticals and health products. The agency's goal is to guarantee the efficacy, safety, and quality of drugs and other medical supplies both during the clinical research process and once they hit the market.\n\nBelgium's Attention Deficit Hyperactivity Disorder (ADHD) therapeutics market is expected to witness growth from $65 Mn in 2022 to $116 Mn in 2030 with a CAGR of 7.5% for the year 2022-2030 due to factors like rising cases of ADHD among the Belgian population and the improved health expenditure for greater access to ADHD medications. The Belgium ADHD therapeutics market is segmented by drug, drug type, demographics, and by distribution channel. Some of the major players in the market include Celyad, Confo Therapeutics, and Advanz Pharmaceuticals. ID: IN10BEPH028 CATEGORY: Pharmaceuticals GEOGRAPHY: Belgium AUTHOR: Parul Choudhary ... The Belgium Attention Deficit Hyperactivity Disorder (ADHD) therapeutics market size is at around $65 Mn in 2022 and is projected to reach $116 Mn in 2030, exhibiting a CAGR of 7.5% during the forecast period. In order to cover higher utility bills, the hospital industry in Belgium will receive $85.43 Mn in the first half of 2023.\n\nThe neurological condition known as Attention Deficit Hyperactivity Disorder (ADHD) is frequently affected by genetics. It is marked by impulsivity, restlessness, or hyperactivity. In the setting of primary care, it is the neurodevelopmental disorder with a childhood onset that is most commonly encountered. Most often, symptoms appear before the age of seven. According to a study by the Belgian Health Care Knowledge Centre (KCE) that was released in 2022, children and adolescents in Belgium between the ages of 6 and 17 are thought to have an ADHD prevalence of about 5.5%. No matter the patient's age, the High Council for Health (SHC) in Belgium emphasizes that the first course of treatment should be psycho-educative therapy, which also involves the patient's family and community. Other approaches should only be contemplated when that fails. Methylphenidate, better known by its brand name Ritalin, is currently the only ADHD drug that is reimbursed in Belgium for patients under the age o",
                "is_citable": true,
                "prompt_context_metadata": {
                  "url": "https://www.insights10.com/report/belgium-adhd-attention-deficit-hyperactivity-disorder-therapeutic-market-analysis/"
                }
              },
              {
                "type": "knowledge",
                "title": "Authorised medicines in Belgium | FAMHP",
                "url": "https://www.famhp.be/en/human_use/medicines/medicines/information_about_medicines/authorised_medicines_in_belgium",
                "metadata": {
                  "type": "webpage_metadata",
                  "site_domain": "famhp.be",
                  "favicon_url": "https://www.google.com/s2/favicons?sz=64&domain=famhp.be",
                  "site_name": "Famhp"
                },
                "is_missing": false,
                "text": "Medicines may only be marketed in Belgium if they are authorised or registered. All authorised medicines are listed in the FAMHP&#x27;s medicinal products database, which includes medicines for human and veterinary use.\n\nMedicines may only be marketed in Belgium if they are authorised or registered. All authorised medicines are listed in the FAMHP's medicinal products database, which includes medicines for human and veterinary use. Under the 'More' section of the medicinal products database, you can find useful information on how to use the database, explanations of the patient information leaflet and the summary of product characteristics (SPC), a list of frequently asked questions and a glossary. Please read this information carefully. Did you know that there is a difference between an authorised medicine and a commercialised medicine? If the quality, safety and efficacy of a medicine has been demonstrated, it can be authorised in Belgium. Once authorised, a medicine may be sold in Belgium. But not all firms choose to market or commercialise their medicine in Belgium.\n\nTherefore it may well be that a medicine has been authorised in Belgium, but be commercialised here. The database contains all authorised medicines.",
                "is_citable": true,
                "prompt_context_metadata": {
                  "url": "https://www.famhp.be/en/human_use/medicines/medicines/information_about_medicines/authorised_medicines_in_belgium"
                }
              },
              {
                "type": "knowledge",
                "title": "Taking stimulants abroad - ADxS.org",
                "url": "https://www.adxs.org/en/page/458/taking-stimulants-abroad",
                "metadata": {
                  "type": "webpage_metadata",
                  "site_domain": "adxs.org",
                  "favicon_url": "https://www.google.com/s2/favicons?sz=64&domain=adxs.org",
                  "site_name": "Adxs"
                },
                "is_missing": false,
                "text": "Stimulants (methylphenidate / MPH and amphetamine medication / AMP) are legally narcotics (BtM) in Germany (along with many other substances). This arti...\n\nAccording to information from the US Embassy in Berlin and the responsible health department dated 24.01.2025 is required: A certificate (in English) stating that the medication is being taken on an ongoing basis for medical reasons. There is no form for this. It must include: ... Signature and stamp of the doctor. A certification from the responsible health authority. The health authority certifies ... The preparation must be carried in the original container in the appropriate quantity for the travel period. in the original container = blister or tin. Cardboard packaging is not required. You may only take as much as is required for the travel time according to the prescription = no quantities that deviate significantly from the travel time · Risk otherwise: US authorities could assume the intention of illegal drug trafficking · According to the public health department, it is not necessary to actively show the documents when entering the country.\n\nDiese Seite wurde am 15.03.2025 zuletzt aktualisiert.\n\nWhen traveling to EU countries that are members of the Schengen Agreement, narcotics that have been acquired on the basis of a medical prescription may be imported and exported as travel requirements in the quantity required for the duration of the trip. For this purpose, a certificate completed by a doctor for the carrying of narcotics in the context of medical treatment in accordance with Article 75 of the Schengen Implementation Agreement Must be carried. Download the Schengen certificate. The certificate must be certified by the state health authority responsible in the respective federal state. An identity card or passport must be presented for certification and is subject to a fee (e.g. EUR 5 in Berlin, EUR 35 elsewhere). Only people with ADHD are permitted to take them with them, not third parties. The certificate is valid for 30 days from the date of issue.\n\nWithin a country, however, it is advisable (especially for drivers) to carry a doctor’s confirmation that stimulants are prescribed. The ADHD ID card from adhspedia can be helpful. When driving in the Czech Republic, however, such a card could pose a risk (see below). The following applies to the transportation of stimulants to countries outside the Schengen Agreement: The regulations of all transit and travel countries must be observed. This applies in any case when traveling by car / bus / train. We do not know whether the regulations of the countries of transfer airports must also be observed when flying. ... Carriage of narcotics for max. 30 days2 · have this certificate notarized by the health authority of the respective federal state · carry a notarized certificate with you during the entire trip ... Attention; lengthy procedure! A list of the requirements can be found at Country-specific entry requirements, International Narcotics Control Board.",
                "is_citable": true,
                "prompt_context_metadata": {
                  "url": "https://www.adxs.org/en/page/458/taking-stimulants-abroad"
                }
              },
              {
                "type": "knowledge",
                "title": "ADHD Medications: How They Work & Side Effects",
                "url": "https://my.clevelandclinic.org/health/treatments/11766-adhd-medication",
                "metadata": {
                  "type": "webpage_metadata",
                  "site_domain": "clevelandclinic.org",
                  "favicon_url": "https://www.google.com/s2/favicons?sz=64&domain=clevelandclinic.org",
                  "site_name": "Cleveland Clinic"
                },
                "is_missing": false,
                "text": "ADHD medication treats the symptoms of attention-deficit/hyperactivity disorder. They work by increasing the levels of certain neurotransmitters in your brain.\n\nADHD medications include stimulants and non-stimulants. Healthcare providers often prescribe antidepressants, as well. Stimulants are the most common type of prescription medication healthcare providers use to treat ADHD. Despite their name, stimulants don’t work by increasing your stimulation. Rather, they work by increasing levels of certain chemicals (neurotransmitters) in your brain called dopamine and norepinephrine. These neurotransmitters play important roles in your ability to pay attention, think and stay motivated. Studies have shown that approximately 80% of children with ADHD have fewer symptoms after finding the correct stimulant medication and dosage. Stimulants are considered controlled substances, which means they have the potential to be improperly used or cause substance use disorders. However, under the care and supervision of your provider, stimulant medication use is safe.\n\nBefore they prescribe you a stimulant, your provider may order an electrocardiogram (EKG) screening to avoid complications from a previously undetected heart rhythm issue. In the United States, some states have laws that tightly restrict the quantity of stimulant medications that you can receive at one time. For example, you may not be able to get more than a 30-day supply before requesting a refill. ... Immediate-release (short-acting): You normally take these stimulants as needed. They can last for up to four hours. When people with ADHD are coming down off a short-acting stimulant dose, they can experience what’s often referred to as “the crash” or “the rebound effect.” It typically involves a sharp decrease in energy level, and it commonly causes severe hunger. Some people experience an intense drop in mood or depression. Extended-release (intermediate-acting or long-acting): You typically take these stimulants once in the morning each day.\n\nMost stimulants fall into one of two drug classes: methylphenidates or amphetamines. Drug classifications group medications together by their similarities, such as active ingredients or approved use. ... Non-stimulants are prescription medications, but they’re not controlled substances like stimulants. That means you’re less likely to improperly use or become dependent on them. They work by increasing the levels of norepinephrine in your brain. Non-stimulant medications for ADHD take longer to start working than stimulants. You may not feel the full effects of these medications until you’ve been taking them regularly for three to four weeks. However, these medications can also help you improve your attention, focus and impulsivity. They can work for up to 24 hours. Your healthcare provider may prescribe a non-stimulant for various reasons, including: Stimulants aren’t effective.",
                "is_citable": true,
                "prompt_context_metadata": {
                  "age": "September 8, 2023",
                  "url": "https://my.clevelandclinic.org/health/treatments/11766-adhd-medication"
                }
              },
              {
                "type": "knowledge",
                "title": "ADHD Medications List: Stimulants and Nonstimulants",
                "url": "https://www.healthline.com/health/adhd/medication-list",
                "metadata": {
                  "type": "webpage_metadata",
                  "site_domain": "healthline.com",
                  "favicon_url": "https://www.google.com/s2/favicons?sz=64&domain=healthline.com",
                  "site_name": "Healthline"
                },
                "is_missing": false,
                "text": "ADHD is commonly treated with prescription medications. See a full list of drugs, including stimulants, nonstimulants, and more.\n\nMedically reviewed by Andy Watkins-McCall, MD, MPH — Written by Kristeen Cherney — Updated on March 28, 2025 · Stimulants are the most common ADHD medications, but they don’t work for everyone. Nonstimulants have fewer side effects but take longer to work. If you have attention deficit hyperactivity disorder (ADHD), you may find it difficult to manage forgetfulness or have difficulty concentrating. These are common symptoms of ADHD. A number of prescription medications are available to help you manage these symptoms and any others you may be experiencing. Treatment approaches vary between children and adults. ... Make sure you fully understand the possible side effects and drug interactions of your medication, and take it only as a healthcare professional prescribes. Read the drug manufacturer’s information leaflet that comes with your prescription.\n\nTreating and dealing with ADHD. (2023). https://www.fda.gov/consumers/consumer-updates/treating-and-dealing-adhd · Verplaetse TL, et al. (2019). Pharmacokinetics and pharmacodynamics of immediate release vs. extended release guanfacine in adult daily smokers. https://pmc.ncbi.nlm.nih.gov/articles/PMC6391212/ ... Medically reviewed by Andy Watkins-McCall, MD, MPH — Written by Kristeen Cherney — Updated on March 28, 2025 ... Limerence refers to a deep need for approval and acceptance. Some people with ADHD may be more prone to experiencing it.READ MORE ... If you have attention deficit hyperactivity disorder (ADHD), meal prep can be more complex, but it can still be manageable with the right approach…READ MORE ... Individuals with attention deficit hyperactivity disorder (ADHD) may be more likely to experience insomnia and other sleep disturbances.\n\nFDA-approved amphetamines for the treatment of ADHD include: ... Depending on your doctor’s recommendations, you may take amphetamines orally as immediate release (IR) or extended release (ER or XR) capsules or tablets. Some brand-name amphetamines with generic forms available include: ... Methylphenidate blocks the reuptake of norepinephrine and dopamine in the brain, increasing the levels of these hormones and alertness while blocking hyperactivity. You take methylphenidate orally. It’s available in the following forms: ... Methylphenidate also comes as an FDA-approved transdermal patch under the brand name Daytrana. Daytrana doesn’t have a generic form. Quillivant XR and QuilliChew ER are FDA-approved methylphenidate formulations without generic versions. FDA-approved brand names for oral methylphenidate with available generic forms include: ...\n\nClonidine is approved to reduce hyperactivity, impulsiveness, and distractibility with ADHD. Healthcare professionals may prescribe other forms of clonidine to treat high blood pressure. Because it also lowers blood pressure, a common side effect of clonidine is lightheadedness in people with ADHD. This drug is available as a generic called clonidine hydrochloride or under the brand name Onyda XR. »More on this:What you need to know about clonidine and cost · Guanfacine is commonly prescribed for high blood pressure in adults. This drug has generic versions, but the FDA has only approved the ER version and its generics for use in children with ADHD. The ER version is called Guanfacine ER (Intuniv). ... A: Yes, in most cases. However, the dosages of many of these drugs are different for kids than they are for adults. Also, the side effects are different in adults than in children.",
                "is_citable": true,
                "prompt_context_metadata": {
                  "age": "March 28, 2025",
                  "url": "https://www.healthline.com/health/adhd/medication-list"
                }
              },
              {
                "type": "knowledge",
                "title": "ADHD Medications Approved by the US FDA (infographic) - CHADD",
                "url": "https://chadd.org/about-adhd/adhd-medications-approved-by-the-us-fda/",
                "metadata": {
                  "type": "webpage_metadata",
                  "site_domain": "chadd.org",
                  "favicon_url": "https://www.google.com/s2/favicons?sz=64&domain=chadd.org",
                  "site_name": "CHADD"
                },
                "is_missing": false,
                "text": "Treatment of ADHD with medication is most effective for reducing the core symptoms of ADHD—inattention, hyperactivity and impulsivity. The US Food and Drug Administration (FDA) has approved several kinds of medications for ADHD that include stimulants (methylphenidate-based and amphetamine-based products) and nonstimulants including atomoxetine and antihypertensives (alpha-2 adrenergic agonists). These medications are listed in the…\n\nTreatment of ADHD with medication is most effective for reducing the core symptoms of ADHD—inattention, hyperactivity and impulsivity. The US Food and Drug Administration (FDA) has approved several kinds of medications for ADHD that include stimulants (methylphenidate-based and amphetamine-based products) and nonstimulants including atomoxetine and antihypertensives (alpha-2 adrenergic agonists). These medications are listed in the chart below which shows: ... Safety recall: Azurity Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Zenzedi® (dextroamphetamine sulfate tablets, USP) 30 mg Due to a Mislabeled Package During Manufacturing ... The information provided by CHADD’s National Resource Center on ADHD is supported by Cooperative Agreement Number NU38DD000002 funded by the Centers for Disease Control and Prevention (CDC). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the CDC or the Department of Health and\n\nIdentifying Misinformation About ADHD Ask The Expert",
                "is_citable": true,
                "prompt_context_metadata": {
                  "age": "December 2, 2023",
                  "url": "https://chadd.org/about-adhd/adhd-medications-approved-by-the-us-fda/"
                }
              },
              {
                "type": "knowledge",
                "title": "Upcoming ADHD Medications: What to Expect in 2025 - Spark Mental Health",
                "url": "https://www.sparkmentalhealth.com/upcoming-adhd-medications-what-to-expect-in-2025/",
                "metadata": {
                  "type": "webpage_metadata",
                  "site_domain": "sparkmentalhealth.com",
                  "favicon_url": "https://www.google.com/s2/favicons?sz=64&domain=sparkmentalhealth.com",
                  "site_name": "Spark Mental Health"
                },
                "is_missing": false,
                "text": "Explore new ADHD medications in 2025, their benefits, and expert insights to stay informed about the latest treatment options.\n\nThe landscape of ADHD medications is evolving rapidly, with new ADHD medications in 2025 promising improved efficacy and fewer side effects. These advancements could revolutionize how we manage ADHD symptoms and enhance the quality of life for millions of individuals worldwide. The ADHD medication market currently features two primary classes: stimulants and non-stimulants. Stimulants, including methylphenidate and amphetamines, serve as the first-line treatment for many patients. These medications increase dopamine levels in the brain, which improves focus and reduces hyperactivity. Non-stimulants, such as atomoxetine and guanfacine, provide an alternative for individuals who don’t respond well to stimulants or have contraindications. Current ADHD medications, while effective for many, present significant drawbacks. Side effects remain a major concern, with appetite suppression, sleep disturbances, and mood changes frequently reported.\n\nThe landscape of ADHD treatment will transform significantly by 2025. New ADHD medications in 2025 will offer more effective symptom management with fewer side effects. These advancements include innovative non-stimulant approaches, novel delivery methods, and promising combination therapies that will revolutionize patient care. Healthcare providers will have greater flexibility to tailor treatment plans to individual patient needs as more options become available. This personalized approach, combined with improved medication adherence, has the potential to enhance outcomes for individuals with ADHD. Patients, caregivers, and healthcare professionals must stay informed about these emerging treatment options to make informed decisions about ADHD management. Spark Mental Health provides personalized, evidence-based care for individuals with ADHD and other mental health conditions.\n\nThe landscape of ADHD treatment stands on the brink of significant change. Researchers explore innovative approaches to address the limitations of current medications. This chapter highlights the most promising developments in ADHD drug research and their potential impact on patient care. Several non-stimulant medications show promise in late-stage clinical trials. A selective norepinephrine reuptake inhibitor (SNRI) demonstrates potential for improved symptom control. A recent study assessed the effectiveness of SNRIs in managing ADHD symptoms, adding to our understanding of these medications. Another exciting development targets the glutamate system. Early results indicate it may help with both attention deficits and emotional regulation, addressing a broader spectrum of ADHD symptoms. This could benefit the estimated 50-70% of adults with ADHD who also experience emotional dysregulation (according to a 2024 study in the Journal of Clinical Psychiatry).\n\nThe concept of combining different medications to target multiple aspects of ADHD gains traction. A notable trial investigates the synergistic effects of a stimulant medication with a non-stimulant alpha-2 agonist. Preliminary results indicate this combination may provide more comprehensive symptom control while allowing for lower doses of each medication, potentially reducing side effects. Another intriguing study explores the combination of ADHD medication with a cognitive enhancer typically used in Alzheimer’s treatment. This approach aims to address not only core ADHD symptoms but also associated cognitive deficits that can persist even with traditional ADHD treatment. Interestingly, a recent study suggests that adult ADHD is associated with an increased risk of dementia, highlighting the importance of reliable assessment in adulthood. While these developments show promise, it’s important to note that not all medications in clinical trials will reach the market.",
                "is_citable": true,
                "prompt_context_metadata": {
                  "age": "February 23, 2025",
                  "url": "https://www.sparkmentalhealth.com/upcoming-adhd-medications-what-to-expect-in-2025/"
                }
              },
              {
                "type": "knowledge",
                "title": "ADHD medicine consumption in Europe after COVID-19: catch-up or trend change? | BMC Psychiatry | Full Text",
                "url": "https://bmcpsychiatry.biomedcentral.com/articles/10.1186/s12888-024-05505-9",
                "metadata": {
                  "type": "webpage_metadata",
                  "site_domain": "biomedcentral.com",
                  "favicon_url": "https://www.google.com/s2/favicons?sz=64&domain=biomedcentral.com",
                  "site_name": "Biomedcentral"
                },
                "is_missing": false,
                "text": "Although the COVID-19 pandemic and its implications have been associated with mental health services utilization and medication consumption, there is no longitudinal study on the long-term impact on ADHD medication use trends. This study examines the European ADHD medication consumption in 2020 to 2022 compared to the predicted consumption assuming the persistence of pre-pandemic trends. Predictions are calculated using Seasonal Autoregressive Integrated Moving Average (SARIMA) models. While European ADHD medication sales recorded a drop in 2020, they returned to the predicted level in 2021, even slightly exceeding it. In 2022, we found a clear exceedance of the predicted level by 16.4% on average at country level. Furthermore, the increase in consumption growth in the post-pandemic period (2021–2022) compared to the pre-pandemic period (2014–2019) was significant in 26 of the 28 European countries under consideration.\n\nBackground Although the COVID-19 pandemic and its implications have been associated with mental health services utilization and medication consumption, there is no longitudinal study on the long-term impact on ADHD medication use trends. Methods This study examines the European ADHD medication consumption in 2020 to 2022 compared to the predicted consumption assuming the persistence of pre-pandemic trends. Predictions are calculated using Seasonal Autoregressive Integrated Moving Average (SARIMA) models. Results While European ADHD medication sales recorded a drop in 2020, they returned to the predicted level in 2021, even slightly exceeding it. In 2022, we found a clear exceedance of the predicted level by 16.4% on average at country level. Furthermore, the increase in consumption growth in the post-pandemic period (2021–2022) compared to the pre-pandemic period (2014–2019) was significant in 26 of the 28 European countries under consideration.\n\nAdditionally, we analyzed the differences in active substances of ADHD medication. They can be divided into stimulants (amfetamine, dexmethylphenidate, lisdexamfetamine, methylphenidate), which are recommended as first-line pharmacological treatment, and non-stimulants (atomoxetine and guanfacine), which are recommended for patients who cannot tolerate stimulants, do not benefit from them or who suffer from substance use disorders [9, 19]. The effects can last 3–5 h (short-acting) or 8–12 h (long-acting). To further quantify the impact of the COVID-19 pandemic on ADHD medicine consumption, we forecasted the sales volume of the years 2020 to 2022 based on the national consumption trends until 2019. The impact was assessed by fitting a SARIMA model [10] and comparing its predictions to the actual sales volume. We used R [22], version 4.1.3, for data analysis.\n\nComparing ADHD medication consumption by active substances (Table 2), we found increasing trends in all substances. Stimulants (methylphenidate, amfetamine, lisdexamfetamine or dexamfetamine) are by far the most frequently prescribed medications, followed by non-stimulants (atomoxetine or guanfacine). Methylphenidate has the highest share of the European consumption, however, due to rapid growth of lisdexamfetamine medications, its share decreases steadily (Fig. 1). We also found that consumption of long-acting medications increased stronger than prescriptions of short-acting medications, which accounted for 21% of total European consumption in 2014, but for only 15% in 2022 (Table 3). Table 2 Annual ADHD medicine consumption by substance in Europe, in DDD per 1000 inhabitants per day. DDD = defined daily dose ... Share of substances on European ADHD medication consumption.",
                "is_citable": true,
                "prompt_context_metadata": {
                  "url": "https://bmcpsychiatry.biomedcentral.com/articles/10.1186/s12888-024-05505-9"
                }
              },
              {
                "type": "text",
                "text": "<system>You only have 17 searches left this turn</system>\n\n",
                "uuid": "d08efc1f-8efd-4f47-9130-d5c4398675aa"
              }
            ],
            "is_error": false,
            "message": null,
            "integration_name": null,
            "integration_icon_url": null,
            "display_content": null
          },
          {
            "start_timestamp": "2025-05-28T11:05:20.905713Z",
            "stop_timestamp": "2025-05-28T11:05:37.562287Z",
            "flags": null,
            "type": "text",
            "text": "\n\nBased on my research, I can provide you with a clear picture of amphetamine-based ADHD medications in Belgium, though I should note that the availability appears to be quite limited compared to other countries.\n\n**Current Status of Amphetamine-Based ADHD Medications in Belgium:**\n\nThe evidence suggests that amphetamine-based medications have very limited availability in Belgium. Here's what I found:\n\n**Limited Availability:**\nMethylphenidate, better known by its brand name Ritalin, is currently the only ADHD drug that is reimbursed in Belgium for patients under the age of 18. The official FAMHP (Belgian health agency) list of commercialised stimulant medicines in Belgium includes: Concerta®, Equasym®, Medikinet®, Methylfenidaat Sandoz®, Methylphenidate Mylan®, Rilatine®, Provigil®, Xyrem® en Wakix® - notably, this list consists primarily of methylphenidate-based medications, not amphetamines.\n\n**Limited Evidence of Amphetamine Availability:**\nWhile a market report mentions amphetamine, dextroamphetamine, and lisdexamfetamine in Belgium's ADHD market analysis, and some Belgian university students reported using amphetamines or dextroamphetamine, this appears to be very limited. One study noted that twelve subjects reported using amphetamines or dextroamphetamine out of over 12,000 surveyed students.\n\n**Regulatory Context:**\nMedicines for the treatment of ADHD (e.g. medicines containing the active substance methylphenidate) are mentioned in Belgium's narcotic substances regulations, but amphetamines are not specifically listed in the travel documentation, suggesting they may not be widely prescribed there.\n\n**Practical Reality:**\nThink of Belgium's ADHD medication landscape like a restaurant with a limited menu - while other countries might offer the full spectrum of both methylphenidate and amphetamine-based options, Belgium appears to focus heavily on methylphenidate-based treatments. This creates a situation where patients seeking amphetamine-based treatments might face significant challenges in accessing them, and reimbursement is even more limited (with adults receiving no reimbursement at all for ADHD medications).\n\nIf you're specifically looking for amphetamine-based ADHD medications in Belgium, I'd recommend consulting directly with Belgian healthcare providers or the FAMHP, as the availability appears to be very restricted compared to countries like the US where these medications are more commonly prescribed.",
            "citations": [
              {
                "uuid": "27b50a10-01e3-4ea1-9e82-ba63e77484a8",
                "start_index": 432,
                "end_index": 583,
                "details": {
                  "type": "web_search_citation",
                  "url": "https://www.insights10.com/report/belgium-adhd-attention-deficit-hyperactivity-disorder-therapeutic-market-analysis/"
                }
              },
              {
                "uuid": "a918fa5f-62e3-4695-bf70-e28e572390b7",
                "start_index": 636,
                "end_index": 681,
                "details": {
                  "type": "web_search_citation",
                  "url": "https://www.famhp.be/en/news/1_in_20_university_students_uses_stimulant_medicines_in_order_to_study_better"
                }
              },
              {
                "uuid": "3bcd99a8-7e6f-43e2-90f6-0fd7a8c07335",
                "start_index": 692,
                "end_index": 811,
                "details": {
                  "type": "web_search_citation",
                  "url": "https://www.famhp.be/en/news/1_in_20_university_students_uses_stimulant_medicines_in_order_to_study_better"
                }
              },
              {
                "uuid": "5d7e5007-a017-45d7-88f9-79cd416bfc69",
                "start_index": 990,
                "end_index": 1042,
                "details": {
                  "type": "web_search_citation",
                  "url": "https://www.insights10.com/report/belgium-adhd-attention-deficit-hyperactivity-disorder-therapeutic-market-analysis/"
                }
              },
              {
                "uuid": "e920c081-e77b-4b7d-96af-6ad9d4620351",
                "start_index": 1130,
                "end_index": 1163,
                "details": {
                  "type": "web_search_citation",
                  "url": "https://archpublichealth.biomedcentral.com/articles/10.1186/s13690-022-00816-3"
                }
              },
              {
                "uuid": "0c6c9990-9855-41e3-a5e0-fc563aa77591",
                "start_index": 1219,
                "end_index": 1283,
                "details": {
                  "type": "web_search_citation",
                  "url": "https://archpublichealth.biomedcentral.com/articles/10.1186/s13690-022-00816-3"
                }
              },
              {
                "uuid": "b5eccfd5-c63e-4508-8fc7-9ead6f34708c",
                "start_index": 1347,
                "end_index": 1447,
                "details": {
                  "type": "web_search_citation",
                  "url": "https://www.famhp.be/en/human_use/particular_products/specially_reglemented_substances/narcotics_psychotropics/informations_pour_les_voyageurs"
                }
              }
            ]
          }
        ],
        "updated_at": "2025-05-28T11:05:37.611405Z",
        "attachments": [],
        "files": []
      }
    },
    {
      "id": "474f9a77-6c23-4632-8e98-183d7993315d",
      "role": "human",
      "content": "What’s similar to aerial",
      "created_at": "2025-05-28T11:17:37.510880Z",
      "sequence_order": 2,
      "metadata": {
        "content": [
          {
            "start_timestamp": "2025-05-28T11:17:37.499595Z",
            "stop_timestamp": "2025-05-28T11:17:37.499595Z",
            "flags": null,
            "type": "text",
            "text": "What’s similar to aerial",
            "citations": []
          }
        ],
        "updated_at": "2025-05-28T11:17:37.510880Z",
        "attachments": [],
        "files": []
      }
    },
    {
      "id": "fe288c60-0440-4884-b7cb-0ec1a909f351",
      "role": "assistant",
      "content": " I'd be happy to help clarify what you mean by \"aerial\" - there are several different contexts where this word is used, so let me cover the main ones:\n\n**If you mean aerial photography/videography:**\n- Drone footage\n- Satellite imagery\n- Bird's-eye view photography\n- Overhead shots\n- Top-down perspective\n\n**If you mean aerial acrobatics/sports:**\n- Gymnastics (especially floor and beam routines)\n- Trapeze work\n- Aerial silks/tissues\n- Aerial hoop (lyra)\n- Pole dancing/fitness\n- Circus arts\n- Parkour (some elements)\n\n**If you mean aerial as in \"up in the air\":**\n- Elevated\n- Airborne\n- Flying\n- Suspended\n- Overhead\n- Sky-high\n\n**If you mean aerial antennas:**\n- Radio antennas\n- TV antennas\n- Wireless receivers\n- Broadcast equipment\n\nCould you clarify which context you're thinking about? That way I can give you more specific and useful comparisons or alternatives.",
      "created_at": "2025-05-28T11:17:49.554048Z",
      "sequence_order": 3,
      "metadata": {
        "content": [
          {
            "start_timestamp": "2025-05-28T11:17:42.963996Z",
            "stop_timestamp": "2025-05-28T11:17:48.994661Z",
            "flags": null,
            "type": "text",
            "text": " I'd be happy to help clarify what you mean by \"aerial\" - there are several different contexts where this word is used, so let me cover the main ones:\n\n**If you mean aerial photography/videography:**\n- Drone footage\n- Satellite imagery\n- Bird's-eye view photography\n- Overhead shots\n- Top-down perspective\n\n**If you mean aerial acrobatics/sports:**\n- Gymnastics (especially floor and beam routines)\n- Trapeze work\n- Aerial silks/tissues\n- Aerial hoop (lyra)\n- Pole dancing/fitness\n- Circus arts\n- Parkour (some elements)\n\n**If you mean aerial as in \"up in the air\":**\n- Elevated\n- Airborne\n- Flying\n- Suspended\n- Overhead\n- Sky-high\n\n**If you mean aerial antennas:**\n- Radio antennas\n- TV antennas\n- Wireless receivers\n- Broadcast equipment\n\nCould you clarify which context you're thinking about? That way I can give you more specific and useful comparisons or alternatives.",
            "citations": []
          }
        ],
        "updated_at": "2025-05-28T11:17:49.554048Z",
        "attachments": [],
        "files": []
      }
    },
    {
      "id": "d43e9e9a-6b98-49bb-ada8-b576782ebdb3",
      "role": "human",
      "content": "What’s similar to aderall",
      "created_at": "2025-05-28T11:18:13.230852Z",
      "sequence_order": 4,
      "metadata": {
        "content": [
          {
            "start_timestamp": "2025-05-28T11:18:13.226104Z",
            "stop_timestamp": "2025-05-28T11:18:13.226104Z",
            "flags": null,
            "type": "text",
            "text": "What’s similar to aderall",
            "citations": []
          }
        ],
        "updated_at": "2025-05-28T11:18:13.230852Z",
        "attachments": [],
        "files": []
      }
    },
    {
      "id": "6538943d-3b08-4e4c-8f01-5b93c5fc2a6c",
      "role": "assistant",
      "content": " Several medications work similarly to Adderall by targeting the same brain chemicals (dopamine and norepinephrine). Here are the main alternatives:\n\n**Other Amphetamine-Based Medications:**\n- **Vyvanse (lisdexamfetamine)** - This is probably the closest alternative. The active ingredient in Vyvanse is lisdexamfetamine, which works after being converted by the body into dextroamphetamine. It provides about 10-13 hours of symptom control versus Adderall's shorter duration.\n\n- **Dexedrine (dextroamphetamine)** - This contains only the dextroamphetamine component of Adderall. The combination of dextroamphetamine and amphetamine (Adderall, Adderall XR, Mydayis) is used as part of a treatment program to control symptoms of attention deficit hyperactivity disorder.\n\n- **Mydayis** - A newer, longer-acting formulation of the same amphetamine salts as Adderall, designed to last even longer.\n\n**Methylphenidate-Based Alternatives:**\nWhile chemically different, these work on similar brain pathways:\n- **Ritalin/Concerta (methylphenidate)** - Methylphenidate blocks the reuptake of norepinephrine and dopamine in the brain, increasing the levels of these hormones and alertness while blocking hyperactivity\n- **Focalin (dexmethylphenidate)** - The more active component of methylphenidate\n\nThink of it like different keys that open the same lock - while Adderall contains a mix of amphetamine salts, Vyvanse delivers the same active ingredient (dextroamphetamine) but through a different delivery system that your body has to convert first. This makes Vyvanse harder to abuse and provides steadier symptom control throughout the day.\n\n**Key Differences to Consider:**\n- **Duration**: Vyvanse typically lasts longer than immediate-release Adderall\n- **Abuse potential**: Studies conducted show that lisdexamfetamine dimesylate may have less abuse potential than dextroamphetamine\n- **Side effects**: Generally similar across amphetamine-based medications\n- **Cost**: Generic Adderall is usually cheaper than brand-name alternatives\n\nThe choice between these medications often comes down to how long you need symptom control, your response to different formulations, and practical factors like cost and availability in your location.",
      "created_at": "2025-05-28T11:18:30.093802Z",
      "sequence_order": 5,
      "metadata": {
        "content": [
          {
            "start_timestamp": "2025-05-28T11:18:14.796706Z",
            "stop_timestamp": "2025-05-28T11:18:30.039465Z",
            "flags": null,
            "type": "text",
            "text": " Several medications work similarly to Adderall by targeting the same brain chemicals (dopamine and norepinephrine). Here are the main alternatives:\n\n**Other Amphetamine-Based Medications:**\n- **Vyvanse (lisdexamfetamine)** - This is probably the closest alternative. The active ingredient in Vyvanse is lisdexamfetamine, which works after being converted by the body into dextroamphetamine. It provides about 10-13 hours of symptom control versus Adderall's shorter duration.\n\n- **Dexedrine (dextroamphetamine)** - This contains only the dextroamphetamine component of Adderall. The combination of dextroamphetamine and amphetamine (Adderall, Adderall XR, Mydayis) is used as part of a treatment program to control symptoms of attention deficit hyperactivity disorder.\n\n- **Mydayis** - A newer, longer-acting formulation of the same amphetamine salts as Adderall, designed to last even longer.\n\n**Methylphenidate-Based Alternatives:**\nWhile chemically different, these work on similar brain pathways:\n- **Ritalin/Concerta (methylphenidate)** - Methylphenidate blocks the reuptake of norepinephrine and dopamine in the brain, increasing the levels of these hormones and alertness while blocking hyperactivity\n- **Focalin (dexmethylphenidate)** - The more active component of methylphenidate\n\nThink of it like different keys that open the same lock - while Adderall contains a mix of amphetamine salts, Vyvanse delivers the same active ingredient (dextroamphetamine) but through a different delivery system that your body has to convert first. This makes Vyvanse harder to abuse and provides steadier symptom control throughout the day.\n\n**Key Differences to Consider:**\n- **Duration**: Vyvanse typically lasts longer than immediate-release Adderall\n- **Abuse potential**: Studies conducted show that lisdexamfetamine dimesylate may have less abuse potential than dextroamphetamine\n- **Side effects**: Generally similar across amphetamine-based medications\n- **Cost**: Generic Adderall is usually cheaper than brand-name alternatives\n\nThe choice between these medications often comes down to how long you need symptom control, your response to different formulations, and practical factors like cost and availability in your location.",
            "citations": [
              {
                "uuid": "66e3ae4e-8dcb-41f6-9c54-1efff31b3571",
                "start_index": 268,
                "end_index": 320,
                "details": {
                  "type": "web_search_citation",
                  "url": "https://americanaddictioncenters.org/stimulants/amphetamine/adderall/vs-vyvanse"
                }
              },
              {
                "uuid": "ebf74921-8c35-4371-bc84-9e4e735d9421",
                "start_index": 328,
                "end_index": 390,
                "details": {
                  "type": "web_search_citation",
                  "url": "https://en.wikipedia.org/wiki/Lisdexamfetamine"
                }
              },
              {
                "uuid": "0174a403-7c68-40bf-998a-e113fcfc145a",
                "start_index": 404,
                "end_index": 421,
                "details": {
                  "type": "web_search_citation",
                  "url": "https://americanaddictioncenters.org/stimulants/amphetamine/adderall/vs-vyvanse"
                }
              },
              {
                "uuid": "d8fec45a-6c04-4192-aeb0-1bfd9a987daf",
                "start_index": 580,
                "end_index": 768,
                "details": {
                  "type": "web_search_citation",
                  "url": "https://medlineplus.gov/druginfo/meds/a601234.html"
                }
              },
              {
                "uuid": "9c256516-19de-4482-b5a4-773590d94725",
                "start_index": 1045,
                "end_index": 1208,
                "details": {
                  "type": "web_search_citation",
                  "url": "https://www.healthline.com/health/adhd/medication-list"
                }
              },
              {
                "uuid": "359deb07-f829-438f-9e91-b2af341b9b39",
                "start_index": 1772,
                "end_index": 1880,
                "details": {
                  "type": "web_search_citation",
                  "url": "https://en.wikipedia.org/wiki/Lisdexamfetamine"
                }
              }
            ]
          }
        ],
        "updated_at": "2025-05-28T11:18:30.093802Z",
        "attachments": [],
        "files": []
      }
    }
  ]
}